isoniazid has been researched along with Recrudescence in 300 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 9.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 9.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "Lower plasma concentrations of rifabutin and, perhaps, isoniazid were associated with ARR failure or relapse in patients with tuberculosis and HIV infection treated with twice-weekly therapy." | 9.11 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ( Benator, D; Burman, W; Hodge, T; Jones, B; Khan, A; Peloquin, CA; Silva-Trigo, C; Vernon, A; Weiner, M; Zhao, Z, 2005) |
| "Mycobacterium tuberculosis antigen 85 is induced in vitro by isoniazid (INH); its sustained induction in sputum during tuberculosis (TB) therapy predicts relapse." | 9.09 | Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. ( Dietze, R; Eisenach, K; Ellner, JJ; Johnson, JL; Maciel, E; Palaci, M; Phillips, M; Rocha, LM; Rose, L; Teixeira, L; Wallis, RS; Wells, C, 2001) |
| "A clinical trial was initiated at ALERT, Addis Ababa, Ethiopia, to study the effect of one-year supplementary treatment on the incidence of dapsone-resistant leprosy in lepromatous patients already on dapsone monotherapy." | 9.05 | Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. ( Mengistu, G; Warndorff van Diepen, T, 1985) |
| "Clinical relevance of the effects of genetic variation on isoniazid concentrations and low first-line tuberculosis drug exposures observed require further investigation." | 7.91 | Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. ( Adamson, J; Chirehwa, M; Denti, P; Govender, K; McIlleron, H; Naidoo, A; Naidoo, K; Ncgapu, S; Padayatchi, N; Ramsuran, V; Singh, R; Yende-Zuma, N, 2019) |
| "Every year, over 1 million people develop isoniazid (INH) resistant tuberculosis (TB)." | 7.85 | Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada. ( Chiang, LY; Cook, VJ; Johnston, JC; Krajden, M; Romanowski, K; Roth, DZ; Tang, P, 2017) |
| "Patients treated for tuberculosis (TB) who had rifampicin (RMP) or isoniazid (INH) concentrations measured between 1 January 2005 and 31 December 2012 were studied retrospectively." | 7.83 | Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand. ( Chiu, W; Hu, R; Lewis, C; Maze, MJ; Nisbet, M; Paynter, J, 2016) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 7.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial." | 7.73 | Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005) |
| "A 33-year-old man with AIDS and pleuro-pulmonary tuberculosis was treated with a combination of antituberculous medications for 12 months and with continuation of isoniazid." | 7.68 | Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. ( Jones, WD; Shafer, RW, 1991) |
| "The outcome of isoniazid chemoprophylaxis for tuberculosis was assessed in refugees from Southeast Asia." | 7.67 | Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. ( Aitken, ML; Anderson, KM; Elarth, AM; Miller, WT; Nolan, CM, 1986) |
| "Isoniazid-induced pancreatitis is potentially reversible; early recognition and drug withdrawal are warranted in the appropriate clinical setting." | 6.42 | Recurrent acute pancreatitis after isoniazid. ( Chow, KM; Leung, CB; Li, PK; Szeto, CC, 2004) |
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 5.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| "Isoniazid-induced pancreatitis is potentially reversible: early recognition and drug withdrawal are warranted in the appropriate clinical setting." | 5.37 | Isoniazid-induced recurrent acute pancreatitis. ( Pandey, AS; Surana, A, 2011) |
| "The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment." | 5.35 | Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008) |
| "There was no further recurrence during successful treatment with full doses of rifampicin and pyrazinamide for 1 year." | 5.29 | Recurrent acute pancreatitis induced by isoniazid. ( Chan, HS; Chan, KL; Lai, KN; Lui, SF, 1994) |
| "Using data from the Tuberculosis Trials Consortium Study 22 (development cohort), we assessed relapse and cure isolates to determine the MIC values of isoniazid and rifampin that were below the standard resistance breakpoint (0." | 5.27 | Bacterial Factors That Predict Relapse after Tuberculosis Therapy. ( Alland, D; Boom, WH; Chakravorty, S; Chippada Venkata, UD; Colangeli, R; Connell, R; Diem, L; Dietze, R; Gupta, A; Jedrey, H; Johnson, JL; Kim, S; Ma, S; Mac Kenzie, WR; Okwera, A; Sherman, DR; Sizemore, EE, 2018) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 5.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "The efficacy of isoniazid (INH) prophylaxis in renal allograft recipients who are on long-term immunosuppression in a region highly prevalent for tuberculosis (TB) was studied." | 5.12 | Efficacy of isoniazid prophylaxis in renal allograft recipients. ( Ahmed, E; Akhtar, F; Akhtar, S; Bhatti, S; Naqvi, A; Naqvi, R; Noor, H; Rizvi, A; Saeed, T; Sheikh, R, 2006) |
| "Lower plasma concentrations of rifabutin and, perhaps, isoniazid were associated with ARR failure or relapse in patients with tuberculosis and HIV infection treated with twice-weekly therapy." | 5.11 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ( Benator, D; Burman, W; Hodge, T; Jones, B; Khan, A; Peloquin, CA; Silva-Trigo, C; Vernon, A; Weiner, M; Zhao, Z, 2005) |
| "Mycobacterium tuberculosis antigen 85 is induced in vitro by isoniazid (INH); its sustained induction in sputum during tuberculosis (TB) therapy predicts relapse." | 5.09 | Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. ( Dietze, R; Eisenach, K; Ellner, JJ; Johnson, JL; Maciel, E; Palaci, M; Phillips, M; Rocha, LM; Rose, L; Teixeira, L; Wallis, RS; Wells, C, 2001) |
| "A clinical trial was initiated at ALERT, Addis Ababa, Ethiopia, to study the effect of one-year supplementary treatment on the incidence of dapsone-resistant leprosy in lepromatous patients already on dapsone monotherapy." | 5.05 | Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. ( Mengistu, G; Warndorff van Diepen, T, 1985) |
| "Clinical relevance of the effects of genetic variation on isoniazid concentrations and low first-line tuberculosis drug exposures observed require further investigation." | 3.91 | Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. ( Adamson, J; Chirehwa, M; Denti, P; Govender, K; McIlleron, H; Naidoo, A; Naidoo, K; Ncgapu, S; Padayatchi, N; Ramsuran, V; Singh, R; Yende-Zuma, N, 2019) |
| " Computer-aided clinical trial simulations have suggested that isoniazid and rifampin pharmacokinetic variability best explained poor outcomes." | 3.86 | Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. ( Gumbo, T; Pasipanodya, JG; Srivastava, S, 2012) |
| "Every year, over 1 million people develop isoniazid (INH) resistant tuberculosis (TB)." | 3.85 | Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada. ( Chiang, LY; Cook, VJ; Johnston, JC; Krajden, M; Romanowski, K; Roth, DZ; Tang, P, 2017) |
| "Patients treated for tuberculosis (TB) who had rifampicin (RMP) or isoniazid (INH) concentrations measured between 1 January 2005 and 31 December 2012 were studied retrospectively." | 3.83 | Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand. ( Chiu, W; Hu, R; Lewis, C; Maze, MJ; Nisbet, M; Paynter, J, 2016) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| "To study the efficacy and safety of Category III DOTS treatment (intermittent thrice-weekly rifampicin [RMP], isoniazid [INH] and pyrazinamide for 2 months, followed by RMP and INH for 4 months) under India's Revised National Tuberculosis Control Programme in patients with uncomplicated small unilateral pleural effusion (<1500 ml)." | 3.78 | Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion. ( Chauhan, LS; Jain, NK; Mohan, A; Sharma, SK; Solanki, R, 2012) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 3.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial." | 3.73 | Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005) |
| "To study the probability of acquiring drug resistance to isoniazid (H) and rifampicin (R) on recurrence after treatment success, default and failure, among sputum smear-positive pulmonary tuberculosis (TB) patients treated with standardised short-course chemotherapy." | 3.72 | Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. ( Mori, T; Nampaisan, O; Palittapongarnpim, P; Rhiengtong, D; Supawitkul, S; Uthaivorawit, W; Yanai, H; Yoshiyama, T, 2004) |
| " tuberculosis, reactivation of the disease may be prevented by chemoprophylaxis with isoniazid or rifampicin." | 3.68 | [Indications for chemoprophylaxis of tuberculosis. Arguments for]. ( Nicod, LP, 1993) |
| "A 33-year-old man with AIDS and pleuro-pulmonary tuberculosis was treated with a combination of antituberculous medications for 12 months and with continuation of isoniazid." | 3.68 | Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. ( Jones, WD; Shafer, RW, 1991) |
| "The outcome of isoniazid chemoprophylaxis for tuberculosis was assessed in refugees from Southeast Asia." | 3.67 | Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. ( Aitken, ML; Anderson, KM; Elarth, AM; Miller, WT; Nolan, CM, 1986) |
| "A controlled comparison by the Tuberculosis Chemotherapy Centre, Madras, of the merits of home as compared with sanatorium treatment for pulmonary tuberculosis showed that, at the end of a year of chemotherapy with isoniazid plus p-aminosalicylic acid (PAS), the response of the home patients closely approached that of the sanatorium patients." | 3.64 | Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate. ( ANDREWS, RH; ANGEL, JH; BHATIA, AL; DEVADATTA, S; FOX, W; JANARDHANAM, B; RADHAKRISHNA, S; RAMAKRISHNAN, CV; SUBBAIAH, TV; VELU, S, 1961) |
| "A recent report by the Tuberculosis Chemotherapy Centre, Madras, showed that the response of patients to a year's domiciliary treatment for pulmonary tuberculosis with isoniazid plus p-aminosalicylic acid closely approached that of patients to a year's sanatorium treatment with the same combination of drugs." | 3.64 | Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate. ( ANDREWS, RH; DEVADATTA, S; FOX, W; RADHAKRISHNA, S; RAMAKRISHNAN, CV; SELKON, JB; SOMASUNDARAM, PR; SUBBAIAH, TV; VELU, S, 1960) |
| "This study from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress during the second year of those patients in a 1-year comparison of four domiciliary chemotherapeutic regimens (isoniazid plus PAS and three regimens of isoniazid alone) whose pulmonary tuberculosis had attained bacteriological quiescence at the end of the year of chemotherapy." | 3.64 | Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate. ( ANDREWS, RH; ANGEL, JH; DEVADATTA, S; FOX, W; GANGADHARAM, PR; NARAYANA, AS; RAMAKRISHNAN, CV; SELKON, JB; SOMASUNDARAM, PR; VELU, S, 1961) |
| "The patients with drug susceptible pulmonary tuberculosis treated with 2HRZE/4H2R2 under the supervision by the pharmacists or the patients treated with 2HRZE/4HR by self-administration were followed-up for two years after completion of chemotherapy." | 2.73 | [Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy]. ( Hoshino, H; Mitarai, S; Ogata, H; Ohmori, M; Okumura, M; Uchimura, K; Wada, M; Yoshiyama, T, 2008) |
| "Among persons who were underweight at diagnosis, weight gain of 5% or less between diagnosis and completion of 2-mo intensive phase therapy was moderately associated with an increased relapse risk (18." | 2.72 | Lack of weight gain and relapse risk in a large tuberculosis treatment trial. ( Horsburgh, CR; Khan, A; Reves, R; Sterling, TR; Vernon, A, 2006) |
| "xenopi disease." | 2.71 | Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. ( Campbell, IA; Jenkins, PA, 2003) |
| "The currently recommended treatment for lymph node tuberculosis is 6 months of rifampicin and isoniazid plus pyrazinamide for the first 2 months, given either daily or thrice weekly." | 2.71 | Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens. ( Ananthalakshmi, V; Chandrasekar, K; Jawahar, MS; Kamaludeen, MN; Paramasivan, CN; Prabhakar, R; Rajaram, K; Sivasubramanian, S; Thirithuvathas, AJ, 2005) |
| "115 cases of the senile pulmonary tuberculosis with bacteriological positive were divided into therapy group(group A) and control group(group B1 and B2) randomly." | 2.70 | [Clinical research of pasinizid on retreated sputum positive pulmonary tuberculosis in senilities]. ( Hu, X; Wang, J; Yu, D, 2001) |
| "Rifapentine is a cyclopentyl-substituted rifamycin whose serum half-life is five times that of rifampin." | 2.69 | Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. ( Benator, D; Bozeman, L; Burman, W; Khan, A; Vernon, A, 1999) |
| "Pefloxacin may have a role in the retreatment of pulmonary tuberculosis along with other drugs, as a companion drug in selected cases." | 2.68 | An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis. ( Rao, S, 1995) |
| "The triple combination studied could replace the separate drugs in the initial treatment phase in countries where the bioavailability of the drugs used has been proven." | 2.68 | [Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]. ( Boulahbal, F; Chaulet, P, 1995) |
| "For patients with pulmonary tuberculosis that is resistant to rifampin and isoniazid, even the best available treatment is often unsuccessful." | 2.67 | Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. ( Ackerson, L; Goble, M; Horsburgh, CR; Iseman, MD; Madsen, LA; Waite, D, 1993) |
| "7%]); had similar rates of adverse drug reactions (7." | 2.67 | USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. ( Combs, DL; Geiter, LJ; O'Brien, RJ, 1990) |
| "Relapses have occurred in two of 119 SHRZ6 patients, four of 127 EHRZ6 patients and two of 127 EHR9 patients." | 2.65 | A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. ( , 1984) |
| "Relapse has occurred in 1 of 125 SHRZ6 patients, 3 of 132 EHRZ6, and 2 of 136 EHR9 patients." | 2.65 | A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association. ( , 1982) |
| "In this study, pulmonary tuberculosis was treated on an ambulatory basis, with the patients engaging in their usual activities and with a shortened period of chemotherapy." | 2.64 | Short-duration treatment of pulmonary tuberculosis. ( Pilheu, JA, 1977) |
| "All 33 relapses were with strains sensitive to isoniazid and streptomycin, and 76 per cent of them occurred in the first 3 months after the end of chemotherapy." | 2.64 | Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. ( , 1975) |
| "Treatment of isoniazid-resistant tuberculosis with the WHO standard regimen for new patients resulted in treatment failure, relapse, and acquired multidrug resistance in 11% (6-17), 10% (5-15) and 8% (3-13), respectively; treatment with the standard WHO regimen for previously treated patients resulted in treatment failure in 6% (2-10), relapse in 5% (2-8), and acquisition of multidrug resistance in 3% (0-6)." | 2.55 | Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. ( Benedetti, A; Gegia, M; Menzies, D; van Soolingen, D; Winters, N, 2017) |
| "Isoniazid-induced pancreatitis is potentially reversible; early recognition and drug withdrawal are warranted in the appropriate clinical setting." | 2.42 | Recurrent acute pancreatitis after isoniazid. ( Chow, KM; Leung, CB; Li, PK; Szeto, CC, 2004) |
| "Four patients (2." | 1.91 | Evaluation of treatment regimens and long-term clinical outcomes in patients with isoniazid-resistant pulmonary tuberculosis: a 5-year follow-up. ( Aslan, AF; Bağcı, BA; Ortaköylü, MG; Toprak, S, 2023) |
| "Initial Hr caused a large recurrence excess after the 8-month regimen for new cases (rifampicin for two months), but had little impact on rifampicin-throughout regimens: (6 months, new cases; 3." | 1.56 | The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. ( de Jong, BC; Decroo, T; Gumusboga, M; Hossain, MA; Kya Jai Maug, A; Lynen, L; Mulders, W; Ortuño-Gutiérrez, N; Rieder, HL; Van Deun, A, 2020) |
| "In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M." | 1.48 | Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. ( Alameda-Martin, L; Coates, A; Davies, G; Harrison, T; Hu, Y; Liu, Y; Ortega-Muro, F; Pertinez, H, 2018) |
| "The uveitis was treated with local and systemic anti-inflammatory and immunosuppressive therapy in all patients." | 1.48 | Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis. ( Leong, BCS; Lightman, S; McCluskey, PJ; Tomkins-Netzer, O; Zhang, X, 2018) |
| "We report a rare case of Takayasu's arteritis with isolated pulmonary artery stenosis in the presence of active hepatitis B and latent Mycobacterium tuberculosis infection in a middle-aged Asian woman who initially presented with severe dyspnea on exertion and recurrent syncope, occasional burning chest pains, and fatigue." | 1.46 | Takayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection. ( Franzen, D; Greutmann, M; Kolios, A; Liebscher, F; Pfammatter, T, 2017) |
| "Seventeen (4." | 1.43 | Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. ( Cho, YJ; Kim, SJ; Lee, CT; Lee, JH; Lee, JY; Lee, YJ; Park, JS; Song, J; Yoon, HI, 2016) |
| "Recurrent tuberculosis is a major health burden and may be due to relapse with the original strain or reinfection with a new strain." | 1.42 | Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. ( Banda, L; Chiwaya, A; Clark, TG; Coll, F; Crampin, AC; Glynn, JR; Guerra-Assunção, JA; Harris, D; Houben, RM; Khan, P; Mallard, K; McNerney, R; Mzembe, T; Parkhill, J; Pereira, RP, 2015) |
| "Worldwide highest number of new pulmonary tuberculosis (PTB) cases, was reported from India in 2012." | 1.40 | Correlates of treatment outcomes and drug resistance among pulmonary tuberculosis patients attending tertiary care hospitals of Kolkata, India. ( Bhattacharya, B; Chakraborty, U; Das, A; Das, S; Dey, SK; Goswami, A; Mahapatra, S; Mahapatra, T; Mukherjee, T; Pal, NK; Ray, S, 2014) |
| "Tuberculosis is still a global health problem all over the world despite its mortality has been decreased with effective treatment regimens." | 1.39 | Unfinished battle with childhood tuberculosis: is it curable with less drugs and shorter duration? ( Cinel, G; Çobanoğlu, N; Doğru, D; Göçmen, A; Kiper, N; Köse, M; Koyun, M; Özçelik, U; Pekcan, S; Tana Aslan, A; Yalçın, E, 2013) |
| "Active tuberculosis is common among human immunodeficiency virus (HIV)-infected persons living in tuberculosis-endemic areas, but the hazard of subsequent tuberculosis disease has not been quantified in a single prospective cohort." | 1.39 | Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. ( Arbeit, RD; Bakari, M; Horsburgh, CR; Lahey, T; Mackenzie, T; Maro, I; Matee, M; Mtei, L; Pallangyo, K; von Reyn, CF, 2013) |
| "Pyrazinamide was omitted in 15 cases while rifampicin only in one patient." | 1.38 | Management of and risk factors related to hepatotoxicity during tuberculosis treatment. ( Ağca, S; Arda, H; Babalık, A; Bakırcı, N; Calışır, HC; Cetintaş, G; Kızıltaş, S; Oruç, K, 2012) |
| " In this article, a case series is presented to illustrate the value of individualized TB drug dosing in four patients with low TB drug concentrations." | 1.38 | Therapeutic drug monitoring in the treatment of tuberculosis patients. ( Aarnoutse, R; Boeree, M; Ijdema, D; Magis-Escurra, C; van den Boogaard, J, 2012) |
| " Noncompliance treatment, simulated by a reduced duration and dosing frequency, resulted in a relapse of infection." | 1.38 | Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis. ( Aarnoutse, RE; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; den Bakker, MA; ten Kate, MT; van Soolingen, D; Verbrugh, HA, 2012) |
| "Half the recurrences occurred in the first year since completing treatment." | 1.38 | The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. ( Crampin, AC; French, N; Glynn, JR; Houben, RM; Mboma, S; Mpunga, J; Mwaungulu, L; Mwaungulu, NJ; Mwenibabu, M; Mzemba, T, 2012) |
| "Isoniazid-induced pancreatitis is potentially reversible: early recognition and drug withdrawal are warranted in the appropriate clinical setting." | 1.37 | Isoniazid-induced recurrent acute pancreatitis. ( Pandey, AS; Surana, A, 2011) |
| "The frequency of late recurrences following treatment completion has not been well-studied." | 1.37 | When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
| "Of 250 cases started on Category II retreatment, 209 were relapse cases; of these, 18 were INH-resistant RMP-susceptible, 18 were INH+RMP-resistant and nine were culture-negative." | 1.36 | Risk of relapse and failure after retreatment with the Category II regimen in Nepal. ( Maharjan, B; Shrestha, B; Yoshiyama, T, 2010) |
| "The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment." | 1.35 | Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008) |
| "Treatment with rifampin and pyrazinamide was more effective than treatment with rifampin, isoniazid, and pyrazinamide at reducing the lung CFU count, consistent with past evidence of isoniazid's antagonism in this model." | 1.35 | Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. ( Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K, 2008) |
| "Pyridoxine was given intravenously as an antidote." | 1.34 | [Isoniazid intoxication]. ( Cyran, J; Graf, J; Radunz, W; Scheffold, N, 2007) |
| "To determine the frequency of TB recurrence among MDR (multidrug-resistant) patients who achieved treatment 'success' on standard short-course chemotherapy." | 1.31 | Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. ( Danilova, ID; Espinal, M; Grzemska, M; Migliori, GB; Punga, VV; Raviglione, MC, 2002) |
| "Pyrazinamide, which was readministered last (at the full dose in one case and at progressive doses in the two others), induced a recurrence in two of them." | 1.30 | [Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide]. ( Autret, E; Carré, P; Jonville-Bera, AP; Lemarié, E; Radal, M; Van-Egroo, C, 1998) |
| "Isoniazid resistance was most prevalent, being found in 72% of isolates, followed by streptomycin resistance in 45%." | 1.30 | Drug-resistant tuberculosis in Singapore, 1995 to 1996. ( Boudville, IC; Snodgrass, I; Wong, SY, 1997) |
| "Although relapse was more frequent in patients with positive smears than those with negative smears (9." | 1.30 | Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? ( Bechan, S; Connolly, C; Short, GM; Standing, E; Wilkinson, D, 1998) |
| "The re-treatment pulmonary tuberculosis with positive spits represent 13." | 1.30 | [The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako]. ( Kayantao, D; Keïta, B; Sangaré, S, 1997) |
| "Pyrazinamide, which was re-administered last, induced a recurrence." | 1.30 | -Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-. ( Autret, E; Jonville-Béra, AP; Martel, C; Mazaud, S; Olivier, C; Radal, M, 1998) |
| "One hundred fifty nine retreatment pulmonary tuberculosis cases admitted to Fukujuji Hospital were retrospectively analyzed." | 1.29 | [Retreatment of pulmonary tuberculosis--duration of chemotherapy]. ( Mori, T; Ogata, H; Seita, A; Sugie, T; Sugita, H; Wada, M, 1993) |
| "Culture positive pulmonary tuberculosis occurred in 292 patients." | 1.29 | Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992. ( al Jarad, N; Empey, DW; Gaya, H; Parastatides, S; Paul, EA; Rudd, RM; Sheldon, CD, 1994) |
| "There was no further recurrence during successful treatment with full doses of rifampicin and pyrazinamide for 1 year." | 1.29 | Recurrent acute pancreatitis induced by isoniazid. ( Chan, HS; Chan, KL; Lai, KN; Lui, SF, 1994) |
| "Eleven cases of papulonecrotic tuberculid (PNT) were seen at the Institute of Dermatology, Bangkok, over a 2-year period (1985 to 1986)." | 1.28 | Papulonecrotic tuberculid. Necessity of long-term triple regimens. ( Kullavanijaya, P; Sirimachan, S; Suwantaroj, S, 1991) |
| "Findings of immunologic observation of 35 subjects included into Group III of dispensary observation before and after antirecurring treatment with isoniazid and isoniazid in combination with ethymisole are presented." | 1.28 | [The effect of anti-recurrence treatment with isoniazid in combination with etimizol on the immune reactivity of Group III ambulatory care patients]. ( Lokhov, MG; Makarova, VM; Maslauskene, TP; Savvateeva, VG, 1990) |
| "No relapse was noted among patients with extrapulmonary tuberculosis." | 1.28 | [Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load]. ( Morland, L, 1990) |
| "Three patients presenting with tuberculous lymphadenitis during pregnancy are described." | 1.28 | Reactivation of tuberculous lymphadenitis during pregnancy. ( Khoo, SH; Warner, TT; Wilkins, EG, 1992) |
| "A case is presented of local recurrence of tuberculosis after successful hip arthrodesis, in a patient subsequently found to have active asymptomatic renal tuberculosis." | 1.27 | Reactivated musculoskeletal tuberculosis with concomitant asymptomatic genitourinary infection. ( Lowe, J; Pfau, A; Stein, H, 1983) |
| "Four relapses were seen during the fixed follow-up period." | 1.27 | [Antitubercular therapeutic regimens routinely prescribed in Bas-Rhin and results of treatment]. ( Burghard, G; Chenuet, J; Liard, R; Perdrizet, S; Petitjean, R; Pierau, F; Rempp, M, 1986) |
| "Chemotherapy of pulmonary disease due to Mycobacterium kansaii has not always been successful, and resectional surgery has been used frequently in the treatment of this infection." | 1.25 | Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii. ( Harris, GD; Johanson, WG; Nicholson, DP, 1975) |
| "The incidence of renal tuberculosis has declined slowly in recent years, but its development has also changed." | 1.25 | Destructive forms of renal tuberculosis. ( Marković, V; Petković, S; Petronić, V; Sumarac, Z, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 128 (42.67) | 18.7374 |
| 1990's | 56 (18.67) | 18.2507 |
| 2000's | 56 (18.67) | 29.6817 |
| 2010's | 56 (18.67) | 24.3611 |
| 2020's | 4 (1.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ekqvist, D | 1 |
| Bornefall, A | 1 |
| Augustinsson, D | 1 |
| Sönnerbrandt, M | 1 |
| Nordvall, MJ | 1 |
| Fredrikson, M | 1 |
| Carlsson, B | 1 |
| Sandstedt, M | 1 |
| Simonsson, USH | 1 |
| Alffenaar, JC | 1 |
| Paues, J | 1 |
| Niward, K | 1 |
| Aslan, AF | 1 |
| Ortaköylü, MG | 1 |
| Bağcı, BA | 1 |
| Toprak, S | 1 |
| Van Deun, A | 1 |
| Decroo, T | 1 |
| Kya Jai Maug, A | 1 |
| Hossain, MA | 1 |
| Gumusboga, M | 1 |
| Mulders, W | 1 |
| Ortuño-Gutiérrez, N | 1 |
| Lynen, L | 1 |
| de Jong, BC | 1 |
| Rieder, HL | 1 |
| Singh, AK | 1 |
| Verma, RK | 1 |
| Mukker, JK | 1 |
| Yadav, AB | 1 |
| Muttil, P | 1 |
| Sharma, R | 1 |
| Mohan, M | 1 |
| Agrawal, AK | 1 |
| Gupta, A | 2 |
| Dwivedi, AK | 1 |
| Gupta, P | 1 |
| Gupta, UD | 1 |
| Mani, U | 1 |
| Chaudhari, BP | 1 |
| Murthy, RC | 1 |
| Sharma, S | 1 |
| Bhadauria, S | 1 |
| Singh, S | 1 |
| Rath, SK | 1 |
| Misra, A | 1 |
| Nakatani, Y | 1 |
| Suto, Y | 1 |
| Fukuma, K | 1 |
| Yamawaki, M | 1 |
| Sakata, R | 1 |
| Takahashi, S | 1 |
| Nakayasu, H | 1 |
| Nakashima, K | 1 |
| Dutta, NK | 1 |
| Pinn, ML | 1 |
| Karakousis, PC | 1 |
| Romanowski, K | 1 |
| Chiang, LY | 1 |
| Roth, DZ | 1 |
| Krajden, M | 1 |
| Tang, P | 1 |
| Cook, VJ | 1 |
| Johnston, JC | 1 |
| Liu, Y | 3 |
| Pertinez, H | 3 |
| Ortega-Muro, F | 2 |
| Alameda-Martin, L | 2 |
| Harrison, T | 1 |
| Davies, G | 2 |
| Coates, A | 2 |
| Hu, Y | 3 |
| Thai, PVK | 1 |
| Ha, DTM | 1 |
| Hanh, NT | 1 |
| Day, J | 1 |
| Dunstan, S | 1 |
| Nhu, NTQ | 1 |
| Kiet, VS | 1 |
| Lan, NH | 1 |
| Dung, NH | 2 |
| Lan, NTN | 1 |
| Thuong, NT | 1 |
| Lan, NN | 1 |
| Liễu, PTT | 1 |
| Hồng, NT | 1 |
| Điệp, ĐC | 1 |
| Thanh, NTK | 1 |
| Hội, NV | 1 |
| Nghĩa, NV | 1 |
| Đại, TN | 1 |
| Minh, HQ | 1 |
| Thơm, NV | 1 |
| Farrar, J | 1 |
| Caws, M | 1 |
| Tomkins-Netzer, O | 1 |
| Leong, BCS | 1 |
| Zhang, X | 1 |
| Lightman, S | 1 |
| McCluskey, PJ | 1 |
| Davies, GR | 1 |
| Gillespie, SH | 1 |
| Coates, AR | 1 |
| Colangeli, R | 1 |
| Jedrey, H | 1 |
| Kim, S | 1 |
| Connell, R | 1 |
| Ma, S | 1 |
| Chippada Venkata, UD | 1 |
| Chakravorty, S | 1 |
| Sizemore, EE | 1 |
| Diem, L | 1 |
| Sherman, DR | 1 |
| Okwera, A | 2 |
| Dietze, R | 2 |
| Boom, WH | 1 |
| Johnson, JL | 2 |
| Mac Kenzie, WR | 1 |
| Alland, D | 1 |
| Cohen, DB | 1 |
| Meghji, J | 1 |
| Squire, SB | 1 |
| Magombedze, G | 1 |
| Pasipanodya, JG | 2 |
| Srivastava, S | 2 |
| Deshpande, D | 1 |
| Visser, ME | 1 |
| Chigutsa, E | 1 |
| McIlleron, H | 2 |
| Gumbo, T | 2 |
| Naidoo, A | 1 |
| Chirehwa, M | 1 |
| Ramsuran, V | 1 |
| Naidoo, K | 1 |
| Yende-Zuma, N | 1 |
| Singh, R | 1 |
| Ncgapu, S | 1 |
| Adamson, J | 1 |
| Govender, K | 1 |
| Denti, P | 1 |
| Padayatchi, N | 1 |
| Stagg, HR | 1 |
| Bothamley, GH | 1 |
| Davidson, JA | 1 |
| Kunst, H | 1 |
| Lalor, MK | 1 |
| Lipman, MC | 1 |
| Loutet, MG | 1 |
| Lozewicz, S | 1 |
| Mohiyuddin, T | 1 |
| Abbara, A | 1 |
| Alexander, E | 1 |
| Booth, H | 1 |
| Creer, DD | 1 |
| Harris, RJ | 1 |
| Kon, OM | 1 |
| Loebinger, MR | 1 |
| McHugh, TD | 1 |
| Milburn, HJ | 1 |
| Palchaudhuri, P | 1 |
| Phillips, PPJ | 1 |
| Schmok, E | 1 |
| Taylor, L | 1 |
| Abubakar, I | 1 |
| Maschmann, Rde A | 1 |
| Sá Spies, F | 1 |
| Nunes, Lde S | 1 |
| Ribeiro, AW | 1 |
| Machado, TR | 1 |
| Zaha, A | 1 |
| Rossetti, ML | 1 |
| Huyen, MN | 1 |
| Cobelens, FG | 1 |
| Buu, TN | 1 |
| Lan, NT | 1 |
| Kremer, K | 1 |
| Tiemersma, EW | 1 |
| van Soolingen, D | 3 |
| Caldera, F | 1 |
| Grimes, I | 1 |
| Soni, A | 1 |
| Cordero-Coma, M | 1 |
| Garzo, I | 1 |
| Salazar, R | 1 |
| Franco, M | 1 |
| Calleja, S | 1 |
| Ruiz de Morales, JM | 1 |
| Cinel, G | 1 |
| Kiper, N | 1 |
| Pekcan, S | 1 |
| Koyun, M | 1 |
| Köse, M | 1 |
| Çobanoğlu, N | 1 |
| Tana Aslan, A | 1 |
| Yalçın, E | 1 |
| Doğru, D | 1 |
| Özçelik, U | 1 |
| Göçmen, A | 1 |
| Xia, Y | 1 |
| Goel, S | 1 |
| Harries, AD | 3 |
| Zhang, Z | 1 |
| Gao, T | 1 |
| Wang, L | 1 |
| Cheng, S | 1 |
| Lin, Y | 1 |
| Du, X | 1 |
| Nunn, AJ | 1 |
| Cook, SV | 1 |
| Burgos, M | 1 |
| Rigouts, L | 1 |
| Yorke-Edwards, V | 1 |
| Anyo, G | 1 |
| Kim, SJ | 2 |
| Enarson, DA | 1 |
| Jindani, A | 1 |
| Lienhardt, C | 3 |
| Yegin, EG | 1 |
| Eryuksel, E | 1 |
| Giral, A | 1 |
| Ceyhan, B | 1 |
| Ozdogan, OC | 1 |
| Goswami, A | 1 |
| Chakraborty, U | 1 |
| Mahapatra, T | 1 |
| Mahapatra, S | 1 |
| Mukherjee, T | 1 |
| Das, S | 1 |
| Das, A | 1 |
| Dey, SK | 1 |
| Ray, S | 1 |
| Bhattacharya, B | 1 |
| Pal, NK | 1 |
| Guerra-Assunção, JA | 1 |
| Houben, RM | 2 |
| Crampin, AC | 2 |
| Mzembe, T | 1 |
| Mallard, K | 1 |
| Coll, F | 1 |
| Khan, P | 1 |
| Banda, L | 1 |
| Chiwaya, A | 1 |
| Pereira, RP | 1 |
| McNerney, R | 1 |
| Harris, D | 1 |
| Parkhill, J | 1 |
| Clark, TG | 1 |
| Glynn, JR | 3 |
| Chien, JY | 1 |
| Chen, YT | 1 |
| Wu, SG | 1 |
| Lee, JJ | 2 |
| Wang, JY | 1 |
| Yu, CJ | 1 |
| Acuña-Villaorduña, C | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 1 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Jones-López, EC | 1 |
| Leung, CC | 1 |
| Chan, CK | 1 |
| Chang, KC | 1 |
| Law, WS | 1 |
| Lee, SN | 1 |
| Tai, LB | 1 |
| Leung, EC | 1 |
| Tam, CM | 2 |
| Karoli, R | 1 |
| Fatima, J | 1 |
| Jain, V | 1 |
| Umar, MS | 1 |
| Dobler, CC | 2 |
| Martin, A | 1 |
| Marks, GB | 1 |
| Park, JS | 1 |
| Lee, JY | 1 |
| Lee, YJ | 1 |
| Cho, YJ | 1 |
| Yoon, HI | 1 |
| Lee, CT | 1 |
| Song, J | 1 |
| Lee, JH | 1 |
| Lee, H | 1 |
| Jeong, BH | 1 |
| Park, HY | 1 |
| Jeon, K | 1 |
| Huh, HJ | 1 |
| Lee, NY | 1 |
| Koh, WJ | 1 |
| Chidiac, R | 1 |
| Williamson, JP | 1 |
| Jelfs, PJ | 1 |
| Holland, DP | 1 |
| Hamilton, CD | 1 |
| Stout, JE | 1 |
| Schipani, A | 1 |
| Maze, MJ | 1 |
| Paynter, J | 1 |
| Chiu, W | 1 |
| Hu, R | 1 |
| Nisbet, M | 1 |
| Lewis, C | 1 |
| Jullien, S | 1 |
| Jain, S | 1 |
| Ryan, H | 1 |
| Ahuja, V | 1 |
| Tun, T | 1 |
| Nyunt, WW | 1 |
| Latt, KZ | 1 |
| Samaranayaka, A | 1 |
| Crump, JA | 1 |
| Thinn, KK | 1 |
| Cook, GM | 1 |
| Aung, HL | 1 |
| Gegia, M | 1 |
| Winters, N | 1 |
| Benedetti, A | 4 |
| Menzies, D | 4 |
| Kotecha, D | 1 |
| Sardar, M | 1 |
| Latimer, MD | 1 |
| Liebscher, F | 1 |
| Pfammatter, T | 1 |
| Kolios, A | 1 |
| Greutmann, M | 1 |
| Franzen, D | 1 |
| Wada, M | 3 |
| Okumura, M | 1 |
| Hoshino, H | 1 |
| Mitarai, S | 1 |
| Ohmori, M | 1 |
| Uchimura, K | 1 |
| Yoshiyama, T | 3 |
| Ogata, H | 2 |
| Tasneen, R | 1 |
| Tyagi, S | 1 |
| Williams, K | 1 |
| Grosset, J | 2 |
| Nuermberger, E | 1 |
| Rosenthal, IM | 1 |
| Zhang, M | 1 |
| Almeida, D | 1 |
| Grosset, JH | 1 |
| Nuermberger, EL | 1 |
| Morrone, N | 1 |
| Morrone Junior, N | 1 |
| Braz, AG | 1 |
| Maia, JA | 1 |
| Santin, M | 1 |
| Dorca, J | 1 |
| Alcaide, F | 1 |
| Gonzalez, L | 1 |
| Casas, S | 1 |
| Lopez, M | 1 |
| Guerra, MR | 1 |
| Kestler, M | 1 |
| Reves, R | 2 |
| Belknap, R | 1 |
| Cardona, PJ | 1 |
| Paydar, A | 2 |
| Martin, I | 1 |
| Royce, S | 3 |
| Pai, M | 2 |
| Vernon, A | 6 |
| Burman, W | 5 |
| Madhukar, P | 1 |
| Oxlade, O | 1 |
| Schwartzman, K | 2 |
| Heymann, J | 1 |
| Shrestha, B | 1 |
| Maharjan, B | 1 |
| Ishimaru, D | 1 |
| Ogawa, H | 1 |
| Ito, Y | 1 |
| Shimizu, K | 1 |
| Mohapatra, PR | 1 |
| Hari, DT | 1 |
| Mulliez, P | 1 |
| Mbassi Fouda, FL | 1 |
| Roy Saint-Georges, F | 1 |
| Pandey, AS | 1 |
| Surana, A | 1 |
| Pascopella, L | 1 |
| Deriemer, K | 1 |
| Watt, JP | 1 |
| Flood, JM | 1 |
| Rudd, A | 1 |
| Dolianitis, C | 1 |
| Varigos, G | 1 |
| Howard, A | 1 |
| Losada, I | 1 |
| Cifuentes, C | 1 |
| Martín, C | 1 |
| García, M | 1 |
| Magis-Escurra, C | 1 |
| van den Boogaard, J | 1 |
| Ijdema, D | 1 |
| Boeree, M | 1 |
| Aarnoutse, R | 1 |
| Babalık, A | 1 |
| Arda, H | 1 |
| Bakırcı, N | 1 |
| Ağca, S | 1 |
| Oruç, K | 1 |
| Kızıltaş, S | 1 |
| Cetintaş, G | 1 |
| Calışır, HC | 1 |
| Hsia, EC | 1 |
| Cush, JJ | 1 |
| Matteson, EL | 1 |
| Beutler, A | 1 |
| Doyle, MK | 1 |
| Hsu, B | 1 |
| Xu, S | 1 |
| Rahman, MU | 1 |
| de Steenwinkel, JE | 1 |
| ten Kate, MT | 1 |
| de Knegt, GJ | 1 |
| Verbrugh, HA | 1 |
| Aarnoutse, RE | 1 |
| Boeree, MJ | 1 |
| den Bakker, MA | 1 |
| Bakker-Woudenberg, IA | 1 |
| Ruiz-Moreno, JL | 1 |
| Peña-Santos, G | 1 |
| Mboma, S | 1 |
| Mzemba, T | 1 |
| Mwaungulu, NJ | 1 |
| Mwaungulu, L | 1 |
| Mwenibabu, M | 1 |
| Mpunga, J | 1 |
| French, N | 1 |
| Lahey, T | 1 |
| Mackenzie, T | 1 |
| Arbeit, RD | 1 |
| Bakari, M | 1 |
| Mtei, L | 1 |
| Matee, M | 1 |
| Maro, I | 1 |
| Horsburgh, CR | 3 |
| Pallangyo, K | 1 |
| von Reyn, CF | 1 |
| Sharma, SK | 1 |
| Solanki, R | 1 |
| Mohan, A | 1 |
| Jain, NK | 1 |
| Chauhan, LS | 1 |
| Migliori, GB | 1 |
| Espinal, M | 1 |
| Danilova, ID | 1 |
| Punga, VV | 1 |
| Grzemska, M | 1 |
| Raviglione, MC | 1 |
| Chakaya, JM | 1 |
| Kibuga, D | 1 |
| Ng'ang'a, L | 1 |
| Githui, WA | 1 |
| Mansoer, JR | 1 |
| Gakiria, G | 1 |
| Kwamanga, D | 1 |
| Maende, J | 1 |
| Weiner, M | 2 |
| Benator, D | 3 |
| Peloquin, CA | 2 |
| Khan, A | 5 |
| Weis, S | 1 |
| King, B | 1 |
| Shah, N | 1 |
| Hodge, T | 2 |
| Knapp, JF | 1 |
| Johnson, T | 1 |
| Alander, S | 1 |
| Ratsirahonana, O | 1 |
| Rasolofo Razanamparany, V | 1 |
| Rasolonavalona, T | 1 |
| Rakotonirina, V | 1 |
| Rakotoarisaonina, A | 1 |
| Rakotoherisoa, A | 1 |
| Ralamboson, M | 1 |
| Cauchoix, B | 1 |
| Rakotondramarina, D | 1 |
| Ramarokoto, H | 1 |
| Jenkins, PA | 2 |
| Campbell, IA | 1 |
| Han, JP | 1 |
| Sun, SL | 1 |
| Li, RZ | 1 |
| Zhang, FS | 1 |
| Wang, SC | 1 |
| Cheng, J | 1 |
| Deng, YF | 1 |
| Wang, Y | 1 |
| Yu, CB | 1 |
| Xu, WG | 1 |
| Gao, Z | 1 |
| Fan, BD | 1 |
| Chimzizi, RB | 1 |
| Nyirenda, TE | 1 |
| van Gorkom, J | 1 |
| Salaniponi, FM | 2 |
| Botha, T | 1 |
| Ryffel, B | 1 |
| KLINGE, A | 1 |
| BLOEDORN, H | 1 |
| VERSE, H | 1 |
| DEVADATTA, S | 4 |
| ANDREWS, RH | 3 |
| ANGEL, JH | 2 |
| BHATIA, AL | 1 |
| FOX, W | 6 |
| JANARDHANAM, B | 1 |
| RADHAKRISHNA, S | 4 |
| RAMAKRISHNAN, CV | 6 |
| SUBBAIAH, TV | 2 |
| VELU, S | 4 |
| ECKLEY, GM | 1 |
| WILSON, JL | 1 |
| SELKON, JB | 2 |
| SOMASUNDARAM, PR | 5 |
| GANGADHARAM, PR | 1 |
| NARAYANA, AS | 1 |
| BERNARD, E | 1 |
| KREIS, B | 1 |
| PARIENTE, D | 1 |
| PIERON, R | 1 |
| PRETET, S | 1 |
| KAZANEK, I | 1 |
| PHILLIPS, S | 1 |
| Denk, GU | 1 |
| Bergstermann, KH | 1 |
| Gallmeier, E | 1 |
| Schirra, J | 1 |
| Wagner, H | 1 |
| Göke, B | 1 |
| Lamerz, R | 1 |
| Yanai, H | 1 |
| Rhiengtong, D | 1 |
| Palittapongarnpim, P | 1 |
| Nampaisan, O | 1 |
| Supawitkul, S | 1 |
| Uthaivorawit, W | 1 |
| Mori, T | 2 |
| Moulding, TS | 1 |
| Le, HQ | 1 |
| Rikleen, D | 1 |
| Davidson, P | 1 |
| Lui, SL | 1 |
| Li, FK | 1 |
| Choy, BY | 1 |
| Chan, TM | 2 |
| Lo, WK | 1 |
| Lai, KN | 2 |
| Krasnov, VA | 2 |
| Ursov, IG | 2 |
| Chow, KM | 1 |
| Szeto, CC | 1 |
| Leung, CB | 1 |
| Li, PK | 1 |
| Jasmer, RM | 2 |
| Bozeman, L | 2 |
| Cave, MD | 1 |
| Saukkonen, JJ | 1 |
| Metchock, B | 1 |
| Burman, WJ | 1 |
| Mok, MY | 1 |
| Lo, Y | 1 |
| Wong, WS | 1 |
| Lau, CS | 1 |
| Jones, B | 1 |
| Silva-Trigo, C | 1 |
| Zhao, Z | 1 |
| Jawahar, MS | 2 |
| Rajaram, K | 1 |
| Sivasubramanian, S | 2 |
| Paramasivan, CN | 2 |
| Chandrasekar, K | 1 |
| Kamaludeen, MN | 1 |
| Thirithuvathas, AJ | 1 |
| Ananthalakshmi, V | 1 |
| Prabhakar, R | 1 |
| Currie, GP | 1 |
| Emmanuel, FX | 1 |
| Ford, D | 1 |
| Devereux, G | 1 |
| Balabanova, Y | 1 |
| Drobniewski, F | 2 |
| Fedorin, I | 1 |
| Zakharova, S | 1 |
| Nikolayevskyy, V | 1 |
| Atun, R | 1 |
| Coker, R | 1 |
| Ayles, H | 1 |
| Muyoyeta, M | 1 |
| Sterling, TR | 2 |
| Naqvi, R | 1 |
| Akhtar, S | 1 |
| Noor, H | 1 |
| Saeed, T | 1 |
| Bhatti, S | 1 |
| Sheikh, R | 1 |
| Ahmed, E | 1 |
| Akhtar, F | 1 |
| Naqvi, A | 1 |
| Rizvi, A | 1 |
| Goldstein, HB | 1 |
| Siefring, RP | 1 |
| Veziris, N | 1 |
| Aubry, A | 1 |
| Truffot-Pernot, C | 2 |
| Graf, J | 1 |
| Scheffold, N | 1 |
| Radunz, W | 1 |
| Cyran, J | 1 |
| Ustinova, EI | 1 |
| Dresviannikov, VM | 1 |
| Liapin, SL | 1 |
| Bezrukavaia, TI | 1 |
| Zakharenko, GP | 1 |
| Kukushkina, LN | 1 |
| Marinina, NV | 1 |
| Kibadi, K | 1 |
| Somner, AR | 1 |
| Hopewell, PC | 2 |
| Sanchez-Hernandez, M | 1 |
| Baron, RB | 1 |
| Ganter, B | 1 |
| Shennan, DH | 2 |
| Comstock, GW | 1 |
| Dutt, AK | 3 |
| Moers, D | 2 |
| Stead, WW | 4 |
| Snider, DE | 5 |
| Jones, WD | 2 |
| Good, RC | 1 |
| Valenzuela, P | 1 |
| Valenzuela, MT | 1 |
| Graczyk, J | 2 |
| Bek, E | 3 |
| Rogowski, J | 1 |
| Foley, HT | 1 |
| Donohoe, RF | 1 |
| Ahn, CH | 1 |
| Lowell, JR | 1 |
| Ahn, SS | 1 |
| Ahn, SI | 1 |
| Hurst, GA | 1 |
| Maskeev, KM | 1 |
| Shefer, LB | 1 |
| Baĭgunov, MA | 1 |
| Kameda, K | 1 |
| Brändli, O | 2 |
| Häcki, MA | 1 |
| Scheel, A | 1 |
| Stiefel, M | 1 |
| Lowe, J | 1 |
| Pfau, A | 1 |
| Stein, H | 1 |
| Reĭkhrud, VM | 1 |
| Zierski, M | 2 |
| Long, MW | 2 |
| Escreet, BC | 1 |
| Cowie, RL | 3 |
| Wagatsuma, H | 1 |
| Degtiarev, VP | 1 |
| Chefranov, VS | 1 |
| Berman, AS | 1 |
| Mochizuki, K | 2 |
| Sarasin, FP | 1 |
| Perrier, A | 1 |
| Rochat, T | 1 |
| Chaulet, P | 2 |
| Boulahbal, F | 1 |
| Smith, TC | 1 |
| Richardus, JH | 1 |
| Chan, KL | 1 |
| Chan, HS | 1 |
| Lui, SF | 1 |
| Rao, S | 1 |
| de Villiers, CL | 1 |
| Macnab, MF | 1 |
| Hawken, M | 1 |
| Nunn, P | 1 |
| Gathua, S | 1 |
| Brindle, R | 1 |
| Godfrey-Faussett, P | 1 |
| Githui, W | 1 |
| Odhiambo, J | 1 |
| Batchelor, B | 1 |
| Gilks, C | 1 |
| Morris, J | 1 |
| Trautmann, M | 1 |
| Ruhnke, M | 1 |
| Held, T | 1 |
| Weinke, T | 1 |
| Mühlberger, F | 1 |
| Nturanye, F | 1 |
| Nasbimana, J | 1 |
| Portaels, F | 1 |
| Chan, SL | 1 |
| Wong, PC | 1 |
| López Gastón, JI | 1 |
| Carod Artal, FJ | 1 |
| al Jarad, N | 1 |
| Parastatides, S | 1 |
| Paul, EA | 1 |
| Sheldon, CD | 1 |
| Gaya, H | 1 |
| Rudd, RM | 1 |
| Empey, DW | 1 |
| Potashova, VA | 1 |
| Zyrianova, TV | 1 |
| Naryshkina, SL | 1 |
| Seita, A | 1 |
| Sugie, T | 1 |
| Sugita, H | 1 |
| Blum, RN | 1 |
| Polish, LB | 1 |
| Tapy, JM | 1 |
| Catlin, BJ | 2 |
| Cohn, DL | 3 |
| Goble, M | 1 |
| Iseman, MD | 1 |
| Madsen, LA | 1 |
| Waite, D | 1 |
| Ackerson, L | 1 |
| Nicod, LP | 1 |
| Kassim, S | 1 |
| Sassan-Morokro, M | 1 |
| Ackah, A | 1 |
| Abouya, LY | 1 |
| Digbeu, H | 1 |
| Yesso, G | 1 |
| Coulibaly, IM | 1 |
| Coulibaly, D | 1 |
| Whitaker, PJ | 1 |
| Doorly, R | 1 |
| Martinez, FD | 1 |
| Hernandez, HM | 1 |
| Kritski, AL | 1 |
| Rodrigues de Jesus, LS | 1 |
| Andrade, MK | 1 |
| Werneck-Barroso, E | 1 |
| Vieira, MA | 1 |
| Haffner, A | 1 |
| Riley, LW | 1 |
| Colmenero, JD | 1 |
| García-Ordoñez, MA | 1 |
| Sebastián, MD | 1 |
| Pérez-Ruiz, E | 1 |
| Sánchez-Lora, J | 1 |
| Sánchez-González, J | 1 |
| Bentabol, G | 1 |
| Juárez, C | 1 |
| Kayantao, D | 1 |
| Keïta, B | 1 |
| Sangaré, S | 1 |
| Boudville, IC | 1 |
| Wong, SY | 1 |
| Snodgrass, I | 1 |
| Barhoumi, C | 1 |
| Masmoudi, AS | 1 |
| Gritli, N | 1 |
| Hamza, M | 1 |
| Nsiri, B | 1 |
| Amor, A | 1 |
| Mechghoul, S | 1 |
| Belhadj, O | 1 |
| Mitchison, DA | 2 |
| Wilkinson, D | 1 |
| Bechan, S | 1 |
| Connolly, C | 1 |
| Standing, E | 1 |
| Short, GM | 1 |
| el-Sadr, WM | 1 |
| Perlman, DC | 1 |
| Matts, JP | 1 |
| Nelson, ET | 1 |
| Salomon, N | 1 |
| Olibrice, M | 1 |
| Medard, F | 1 |
| Chirgwin, KD | 1 |
| Mildvan, D | 1 |
| Jones, BE | 1 |
| Telzak, EE | 1 |
| Klein, O | 1 |
| Heifets, L | 1 |
| Hafner, R | 1 |
| Zeenreich, A | 1 |
| Gochstein, B | 1 |
| Grinshpoon, A | 1 |
| Miron, M | 1 |
| Rosenman, J | 1 |
| Ben-Dov, I | 1 |
| Radal, M | 2 |
| Jonville-Bera, AP | 2 |
| Van-Egroo, C | 1 |
| Carré, P | 1 |
| Lemarié, E | 1 |
| Autret, E | 2 |
| Teo, SK | 1 |
| Olivier, C | 1 |
| Mazaud, S | 1 |
| Martel, C | 1 |
| Xiao, C | 1 |
| Fu, Y | 1 |
| Li, Z | 1 |
| Alwood, K | 1 |
| Gachuhi, R | 1 |
| Coggin, W | 1 |
| Blazes, D | 1 |
| Bishai, WR | 1 |
| Chaisson, RE | 1 |
| Mishin, VIu | 1 |
| Chukanov, VI | 1 |
| Golyshevskaia, VI | 1 |
| Grigor'ev, IuG | 1 |
| Warndorff, DK | 1 |
| Yates, M | 1 |
| Ngwira, B | 1 |
| Chagaluka, S | 1 |
| Pönnighaus, JM | 1 |
| Fine, PE | 1 |
| Amaya-Tapia, G | 1 |
| Martín-Del Campo, L | 1 |
| Aguirre-Avalos, G | 1 |
| Portillo-Gómez, L | 1 |
| Covarrubias-Pinedo, A | 1 |
| Aguilar-Benavides, S | 1 |
| Snyder, DC | 1 |
| Chin, DP | 1 |
| Cuthbert, SS | 1 |
| Antonio Paz, E | 1 |
| Daley, CL | 1 |
| Alici, E | 1 |
| Akçali, O | 1 |
| Tatari, H | 1 |
| Günal, I | 1 |
| Wallis, RS | 1 |
| Phillips, M | 1 |
| Teixeira, L | 1 |
| Rocha, LM | 1 |
| Maciel, E | 1 |
| Rose, L | 1 |
| Wells, C | 1 |
| Palaci, M | 1 |
| Eisenach, K | 1 |
| Ellner, JJ | 1 |
| Sofia, M | 1 |
| Maniscalco, M | 1 |
| Honoré, N | 1 |
| Molino, A | 1 |
| Mormile, M | 1 |
| Heym, B | 1 |
| Cole, ST | 1 |
| Lademarco, MF | 1 |
| Binkin, NJ | 1 |
| Tung, LB | 1 |
| Quy, HT | 1 |
| Cĵ, NV | 1 |
| van Loenhout-Rooyackers, JH | 2 |
| Keyser, A | 1 |
| Laheij, RJ | 1 |
| Verbeek, AL | 2 |
| van der Meer, JW | 1 |
| Hargreaves, NJ | 1 |
| Yu, D | 1 |
| Wang, J | 1 |
| Hu, X | 1 |
| Steinmann, RA | 1 |
| Rickel, MK | 1 |
| Al-Dossary, FS | 1 |
| Ong, LT | 1 |
| Correa, AG | 1 |
| Starke, JR | 1 |
| Jutte, PC | 1 |
| Krüüner, A | 1 |
| Pehme, L | 1 |
| Ghebremichael, S | 1 |
| Koivula, T | 1 |
| Hoffner, SE | 1 |
| Mikelsaar, M | 1 |
| Tuli, SM | 1 |
| Forschbach, G | 1 |
| Farer, LS | 2 |
| Sahn, SA | 1 |
| Lakshminarayan, S | 1 |
| Rose, FC | 1 |
| Nazareth, O | 2 |
| Parthasarathy, R | 1 |
| Santha, T | 2 |
| Sivasubramanian, SS | 1 |
| Subbammal, S | 2 |
| Tripathy, SP | 2 |
| Guernsey, BG | 1 |
| Alexander, MR | 1 |
| Radenbach, KL | 2 |
| Postoiuk, MG | 1 |
| Morgan, EJ | 1 |
| Steiner, A | 1 |
| Medici, TC | 1 |
| Mayock, RL | 1 |
| MacGregor, RR | 1 |
| Pilheu, JA | 1 |
| Geboes, K | 1 |
| Bossaert, H | 1 |
| Reichman, LB | 1 |
| McDonald, RJ | 1 |
| Harris, GD | 1 |
| Johanson, WG | 1 |
| Nicholson, DP | 1 |
| Heffernan, JF | 1 |
| Petković, S | 1 |
| Sumarac, Z | 1 |
| Petronić, V | 1 |
| Marković, V | 1 |
| Warner, TT | 1 |
| Khoo, SH | 1 |
| Wilkins, EG | 1 |
| Lee, KC | 1 |
| Tami, TA | 1 |
| Lalwani, AK | 1 |
| Schecter, G | 1 |
| Kullavanijaya, P | 1 |
| Sirimachan, S | 1 |
| Suwantaroj, S | 1 |
| Bobarykin, VS | 1 |
| Freerksen, E | 1 |
| Alvarenga, AE | 1 |
| Leguizamon, O | 1 |
| de Morra, MV | 1 |
| Reyes, LA | 1 |
| von Ballestrem, W | 1 |
| Wiesner, B | 1 |
| Cramer, G | 1 |
| Hamel, U | 1 |
| Roth, G | 1 |
| Shafer, RW | 1 |
| Peterson, KL | 1 |
| Judson, FN | 1 |
| Sbarbaro, JA | 2 |
| Balasubramanian, R | 1 |
| Vijayan, VK | 1 |
| Ramachandran, R | 1 |
| Selvakumar, N | 1 |
| Savvateeva, VG | 1 |
| Maslauskene, TP | 1 |
| Makarova, VM | 1 |
| Lokhov, MG | 1 |
| Combs, DL | 1 |
| O'Brien, RJ | 1 |
| Geiter, LJ | 1 |
| Morland, L | 1 |
| Li, YD | 1 |
| Warndorff van Diepen, T | 1 |
| Mengistu, G | 1 |
| Lecoeur, HF | 1 |
| Lagrange, PH | 1 |
| Gheorghiu, M | 1 |
| Haegi, V | 1 |
| Villiger, B | 1 |
| Bohn, W | 1 |
| Baumann, HR | 1 |
| Zäch, R | 1 |
| Gel'berg, IS | 1 |
| Romaniuk, SL | 1 |
| Avlasenko, VS | 1 |
| Zharovina, MM | 1 |
| Nardell, E | 1 |
| McInnis, B | 1 |
| Thomas, B | 1 |
| Weidhaas, S | 1 |
| Baba, H | 1 |
| Shinkai, A | 1 |
| Izuchi, R | 1 |
| Azuma, Y | 1 |
| Dal Negro, R | 1 |
| Turco, P | 1 |
| Trevisan, F | 1 |
| De Conti, F | 1 |
| Kleeberg, HH | 1 |
| Lin, TP | 1 |
| Suo, J | 1 |
| Lee, CN | 1 |
| Yang, SP | 1 |
| Leiker, DL | 1 |
| Shigeto, E | 1 |
| Kobayashi, Y | 1 |
| Nagasawa, S | 1 |
| Kovaleva, SI | 2 |
| Dzhokhadze, VA | 1 |
| Nikodemowicz, E | 1 |
| Kamińska, M | 1 |
| Kopeć, H | 1 |
| Maternowska, W | 1 |
| Prus, F | 1 |
| Sembratowicz, L | 1 |
| Berkani, M | 1 |
| Darbyshire, JH | 1 |
| Nunn, A | 1 |
| Liard, R | 1 |
| Perdrizet, S | 1 |
| Burghard, G | 1 |
| Petitjean, R | 1 |
| Rempp, M | 1 |
| Pierau, F | 1 |
| Chenuet, J | 1 |
| Nolan, CM | 1 |
| Aitken, ML | 1 |
| Elarth, AM | 1 |
| Anderson, KM | 1 |
| Miller, WT | 1 |
| Mangla, A | 1 |
| Fisher, J | 1 |
| Libby, DM | 1 |
| Saddekni, S | 1 |
| Grebenkina, AI | 1 |
| Gamperis, IuL | 1 |
| Gavrilenko, AF | 1 |
| Kuznetsova, GG | 1 |
| Riska, H | 1 |
| Pearce, SJ | 1 |
| Horne, NW | 1 |
| Maisey, DN | 1 |
| Brown, RC | 2 |
| Day, JL | 1 |
| Jurgens, GH | 1 |
| Raleigh, JW | 1 |
| Wichelhausen, R | 1 |
| Ross, JD | 1 |
| Chioléro, R | 1 |
| Bartal, M | 1 |
| Nejjar, A | 1 |
| Laraki, A | 1 |
| Lees, AW | 1 |
| Allan, GW | 1 |
| Smith, J | 1 |
| Tyrell, WF | 1 |
| Fallon, RJ | 1 |
| Lester, W | 1 |
| Zaki, MH | 1 |
| Neumann, G | 2 |
| Burzibu, JM | 1 |
| Durante, C | 1 |
| Ceicu, A | 1 |
| el Fassi el Fahri, M | 1 |
| Bahsoun, H | 1 |
| Nicholson, RA | 1 |
| Mattson, K | 1 |
| Hsu, KH | 1 |
| Nitti, V | 1 |
| Constans, P | 1 |
| Baron, A | 1 |
| Parrot, R | 1 |
| Coury, C | 1 |
| Schachter, EN | 1 |
| Karpick, RJ | 1 |
| Curry, FJ | 1 |
| Reimers, D | 1 |
| Kok-Jensen, A | 1 |
| Zierler, W | 1 |
| Abeles, H | 1 |
| Atuk, NO | 1 |
| Gurfinik, NE | 1 |
| Lesnichii, AV | 1 |
| Greene, ME | 1 |
| Stonehill, RB | 1 |
| Boman, G | 1 |
| Dahlström, G | 1 |
| Hanngren, A | 1 |
| Stavenow, S | 1 |
| Wiman, LG | 1 |
| Hudson, LD | 1 |
| Eule, H | 1 |
| Menon, NK | 1 |
| Rajappa, D | 1 |
| Stott, H | 1 |
| Westwater, ML | 1 |
| Bignall, JR | 1 |
| Lind, A | 1 |
| Rist, N | 1 |
| Chan-Yeung, M | 1 |
| Galbraith, JD | 1 |
| Schulson, N | 1 |
| Brown, A | 1 |
| Grzybowski, S | 1 |
| Touraine, R | 1 |
| Roire, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Multicenter Phase II-study: Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in a Shorter Tuberculosis Treatment Compared With Standardized Treatment in Patients With Mild to Moderate Pulmonary TB[NCT04694586] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of An[NCT00130247] | Phase 3 | 394 participants (Actual) | Interventional | 2002-04-08 | Completed | ||
| An Open Label Randomized Controlled Clinical Trial Comparing a 24Week Oral Regimen Containing Moxifloxacin With a 24 Week Standard Drug Regimen for the Treatment of Smear-positive Pulmonary Tuberculosis in Patients Previously Treated for TB[NCT02114684] | Phase 1/Phase 2 | 197 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Inf[NCT01136161] | Phase 2 | 95 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection[NCT00905970] | 105 participants (Anticipated) | Observational | 2009-05-31 | Recruiting | |||
| Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner[NCT00904956] | 12 participants (Anticipated) | Observational | 2009-11-30 | Recruiting | |||
| Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma[NCT05431673] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-08-21 | Not yet recruiting | ||
| DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)[NCT00052195] | Phase 2/Phase 3 | 1,975 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tubercu[NCT00023335] | Phase 3 | 1,000 participants | Interventional | 1995-04-30 | Completed | ||
| Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi[NCT01298336] | Phase 3 | 92 participants (Actual) | Interventional | 2011-03-02 | Completed | ||
| Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy[NCT03941496] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2022-10-31 | Withdrawn (stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.) | ||
| TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen[NCT00023361] | 215 participants | Interventional | 1999-02-28 | Completed | |||
| TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in USPHS Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen[NCT00023348] | Phase 2/Phase 3 | 150 participants | Interventional | 1999-07-31 | Completed | ||
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149] | Phase 2 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Idiopathic Infantile Hypercalcemia[NCT03384121] | Phase 1 | 5 participants (Anticipated) | Interventional | 2018-02-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00130247)
Timeframe: 2 years
| Intervention | Participants (Number) |
|---|---|
| 4-Month Arm | 0 |
| 6-Month Arm | 0 |
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months
| Intervention | Participants (Number) |
|---|---|
| 4-Month Arm | 13 |
| 6-Month Arm | 3 |
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months
| Intervention | Participants (Number) |
|---|---|
| 4-Month Arm | 13 |
| 6-Month Arm | 3 |
(NCT00130247)
Timeframe: 1 and 2 years after successful completion of initial anti-TB treatment
| Intervention | Participants (Number) | |
|---|---|---|
| Relapses at 1 year | Relapses at 2 years | |
| 4-Month Arm | 10 | 13 |
| 6-Month Arm | 3 | 3 |
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years
| Intervention | Participants (Number) | |
|---|---|---|
| Treatment Failures | Relapses | |
| 4-Month Arm | 0 | 13 |
| 6-Month Arm | 0 | 3 |
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years
| Intervention | Participants (Number) | |
|---|---|---|
| Treatment Failures | Relapses | |
| 4-Month Arm | 0 | 13 |
| 6-Month Arm | 0 | 3 |
To compare the proportion of patients with any Grade 3 or 4 adverse reactions in the two study arms. Outcome measured in terms of number of participants with at least one grade 3 or 4 events, and not in number of events. (NCT02114684)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Moxifloxacin | 43 |
| Control | 25 |
A patient was defined as having an unfavourable outcome if he/she was not cured at the end of treatment or did not successfully complete treatment. Recurrence after completion of treatment was defined as two positive cultures within a period of four months without an intervening negative culture. (NCT02114684)
Timeframe: up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Moxifloxacin | 13 |
| Control | 6 |
To determine the time to culture-conversion of the moxifloxacin regimen and the ethambutol regimen. (NCT02114684)
Timeframe: Up to 2 years
| Intervention | weeks (Median) |
|---|---|
| Moxifloxacin | 6.0 |
| Control | 7.9 |
To compare adverse events and 8-week culture conversion rates among HIV-infected patients vs. HIV-uninfected patients. The proportion of participants with at least one grade 3 or 4 adverse event was measured. (NCT02114684)
Timeframe: up to 2 years for adverse events and 8 weeks for culture conversion rates
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| participants with grade 3/4 adverse events | participants culture negative at 8 weeks | |
| HIV Negative, Control | 6 | 22 |
| HIV Negative, Moxifloxacin | 13 | 21 |
| HIV Positive, Control | 19 | 51 |
| HIV Positive, Moxifloxacin | 30 | 57 |
The proportion of patients with negative sputum cultures at the end of the intensive phase (8 weeks) and the proportion of patients with negative sputum cultures at 6 months were compared between the two study arms. All participants with sputum culture results at week 8 and month 6 were included in the analysis. (NCT02114684)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| culture negative at 8 weeks | culture negative at 6 months | |
| Control | 73 | 92 |
| Moxifloxacin | 78 | 84 |
24 reviews available for isoniazid and Recrudescence
| Article | Year |
|---|---|
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Microbial Sensitivity Tests; Recurrence; R | 2018 |
Six-month therapy for abdominal tuberculosis.
Topics: Abdomen; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Humans; Isoniazid; Pyrazin | 2016 |
Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Canada; Humans; Isoniazid; Recurrence; Retreatment; Rifampin; Treatment Failu | 2017 |
Pacemaker wire infection with Mycobacterium tuberculosis: a case report and literature review.
Topics: Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Iso | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.
Topics: Antibiotics, Antitubercular; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Isoni | 2009 |
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Cohort Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans | 2009 |
Surgical treatment of an infant with Bacille Calmette-Guérin osteomyelitis extending across the growth plate.
Topics: Anti-Bacterial Agents; BCG Vaccine; Bone Substitutes; Curettage; Durapatite; Growth Plate; Humans; I | 2011 |
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Isoniazid; Mycobacterium tuberculosis; Pr | 2012 |
Recurrent acute pancreatitis after isoniazid.
Topics: Acute Disease; Adult; Antitubercular Agents; Humans; Isoniazid; Male; Pancreatitis; Recurrence; Tube | 2004 |
Isoniazid to prevent first and recurrent episodes of TB.
Topics: Antitubercular Agents; Humans; Isoniazid; Practice Guidelines as Topic; Recurrence; Tuberculosis | 2006 |
[Trends in tuberculosis treatment duration].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2006 |
[Concept of the relapse of tuberculosis].
Topics: Animals; Humans; Isoniazid; Mice; Recurrence; Rifampin; Tuberculosis, Pulmonary | 1982 |
Complicated tuberculosis and residual disease.
Topics: HIV Seropositivity; Humans; Isoniazid; Recurrence; Risk Factors; Tuberculosis; Tuberculosis, Pulmona | 1994 |
A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam.
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Protocols; Female; Humans; Isoniazid; Male; Middl | 2001 |
Tuberculous meningitis: is a 6-month treatment regimen sufficient?
Topics: Adult; Antitubercular Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; Humans | 2001 |
Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa.
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Admin | 2001 |
Chemotherapeutic treatment for spinal tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Administration Schedule; Fema | 2002 |
[Drug therapy of pulmonary tuberculosis].
Topics: Antitubercular Agents; Cycloserine; Drug Interactions; Drug Therapy, Combination; Ethambutol; Humans | 1978 |
Tuberculosis: review of treatment failure, relapse and drug resistance.
Topics: Aminosalicylic Acid; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Humans; Ison | 1978 |
Diagnosis, prevention and early therapy of tuberculosis.
Topics: Aminosalicylic Acids; Ethambutol; Female; Humans; Hypersensitivity, Delayed; Isoniazid; Male; Mycoba | 1976 |
[Pregnancy and tuberculosis].
Topics: Abortion, Therapeutic; Adult; Antitubercular Agents; Birth Rate; Female; Fetal Diseases; Germany, We | 1974 |
[Chemoprevention and preventive chemotherapy of tuberculosis in adulthood (Review)].
Topics: Adult; Amides; Antitubercular Agents; Ethambutol; Evaluation Studies as Topic; False Negative Reacti | 1974 |
[Current status of chemotherapy of pulmonary tuberculosis and its further prospectives].
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Dr | 1971 |
64 trials available for isoniazid and Recrudescence
| Article | Year |
|---|---|
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
Topics: Adult; Antitubercular Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; | 2022 |
Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Resistance, Bacterial; Female; Humans; Isoniazi | 2018 |
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.
Topics: Africa; Antitubercular Agents; Asia; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol | 2014 |
Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
Topics: Antitubercular Agents; Decision Support Techniques; Ethambutol; Humans; Isoniazid; Markov Chains; Py | 2016 |
[Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Directly Observed Therapy; Drug Administratio | 2008 |
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Isoniazid; Mycobacterium tuberculosis; Pr | 2012 |
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antitubercular Agents; Arthritis; Chemical and Drug Induced Liv | 2013 |
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
Topics: Adult; Analysis of Variance; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availabi | 2003 |
Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Com | 2003 |
Recurrent tuberculosis in the United States and Canada: relapse or reinfection?
Topics: Adult; Antitubercular Agents; Canada; Female; Genotype; Humans; Isoniazid; Male; Mycobacterium tuber | 2004 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Child; Directly Observed Ther | 2005 |
Lack of weight gain and relapse risk in a large tuberculosis treatment trial.
Topics: Adult; Antitubercular Agents; Body Mass Index; Body Weight; Female; Humans; Isoniazid; Male; Middle | 2006 |
Efficacy of isoniazid prophylaxis in renal allograft recipients.
Topics: Antitubercular Agents; Humans; Isoniazid; Kidney Transplantation; Postoperative Complications; Pyrid | 2006 |
Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic Association (third report).
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazi | 1980 |
Operational evaluation of treatment for tuberculosis. Results of a "standard" 12-month regimen in Peru.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Communicable Disease Control; | 1984 |
Comparison of a conventional and an initial 2-month intensive drug regimen for treating pulmonary tuberculosis in Swaziland.
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, | 1984 |
New data on preventive treatment with isoniazid.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Administration Schedule; Huma | 1983 |
A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina | 1984 |
Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Evaluation Studies as Top | 1984 |
A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina | 1982 |
Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Female; Hu | 1980 |
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1981 |
Short-course chemotherapy for pulmonary tuberculosis. A 100-day interrupted regimen.
Topics: Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Drug Administration Schedule; Drug Com | 1981 |
[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Drug Tol | 1995 |
An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Ison | 1995 |
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Resistance, Microbial; Female; Humans; Isoniazi | 1993 |
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul | 1995 |
A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Black People; Body Weight; Drug Administration Sched | 1996 |
Relapse after short-course chemotherapy of patients with sputum smear-positive pulmonary tuberculosis under routine conditions with additional information on side effects and contact tracing.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Drug Admin | 1996 |
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Child; Chi | 1997 |
A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antitubercular Agents; Child; Drug Administration Sch | 1997 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
[Long-term efficacy of full course intermittent short-course chemotherapy on new smear positive tuberculosis patients].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid; | 1997 |
Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Humans; I | 1999 |
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Dr | 1999 |
Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.
Topics: Acyltransferases; Antibiotics, Antitubercular; Antigens, Bacterial; Antitubercular Agents; Biomarker | 2001 |
[Clinical research of pasinizid on retreated sputum positive pulmonary tuberculosis in senilities].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Clinical Protocols; Drug Therapy, | 2001 |
Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
Topics: Adolescent; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Directly Ob | 2002 |
Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Dr | 1976 |
Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1978 |
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E | 1979 |
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E | 1979 |
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E | 1979 |
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E | 1979 |
Efficacy of once-weekly isoniazid-streptomycin in preventing relapse of pulmonary tuberculosis.
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Recurre | 1977 |
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Clinical Trials as Topic; Drug Thera | 1979 |
Short-duration treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Ambulatory Care; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Ma | 1977 |
Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Microbial; Female; | 1975 |
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hon
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug | 1991 |
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Adolescent; Adult; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; | 1991 |
Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Micro | 1990 |
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.
Topics: Adult; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Data Interpretation, | 1990 |
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment.
Topics: Adolescent; Adult; Dapsone; Drug Combinations; Drug Resistance; Humans; Isoniazid; Leprosy; Recurren | 1985 |
[Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Topics: Adult; Antitubercular Agents; Drug Combinations; Ethambutol; Female; Humans; Isoniazid; Male; Middle | 1989 |
Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1988 |
Pulmonary tuberculosis treated with isoprodian and rifampicin or pyrazinamide.
Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Thera | 1987 |
Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients.
Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Iso | 1987 |
Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1986 |
A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as | 1986 |
Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Humans; Isoniazid; | 1985 |
Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Combi | 1972 |
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.
Topics: Adolescent; Adult; Africa, Eastern; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Dr | 1974 |
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Africa; Clinical Trials as Topic; Drug Combinations; Drug E | 1974 |
[Rifampicin in the treatment of active pulmonary tuberculosis. Controlled trial of isoniazid-rifampicin-thiocarlide versus isoniazid-streptomycin-thiocarlide in untreated tuberculosis. Treatment of relapses with the combination rifampicin-ethambutol-thioc
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Hypersensitivity; Drug Therap | 1974 |
Controlled clinical evaluation of three intermittent regimens employing low-dosage schedules of rifampicin in original treatment of pulmonary tuberculosis. Preliminary data on effectiveness and side effects.
Topics: Antibody Formation; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; | 1973 |
Two controlled studies of the efficacy of isoniazid alone in preventing relapse in patients with bacteriologically quiescent pulmonary tuberculosis at the end of one year of chemotherapy.
Topics: Clinical Trials as Topic; Follow-Up Studies; Humans; India; Isoniazid; Recurrence; Tuberculosis, Pul | 1971 |
213 other studies available for isoniazid and Recrudescence
| Article | Year |
|---|---|
Evaluation of treatment regimens and long-term clinical outcomes in patients with isoniazid-resistant pulmonary tuberculosis: a 5-year follow-up.
Topics: Antitubercular Agents; Follow-Up Studies; Humans; Isoniazid; Recurrence; Retrospective Studies; Trea | 2023 |
The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.
Topics: Adult; Antitubercular Agents; Bangladesh; Diagnostic Errors; Drug Resistance; Fluoroquinolones; Huma | 2020 |
Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Guine | 2021 |
Intrathecal Isoniazid for Refractory Tuberculous Meningitis with Cerebral Infarction.
Topics: Adult; Anti-Inflammatory Agents; Anticoagulants; Antitubercular Agents; Asian People; Cerebral Infar | 2017 |
Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy | 2017 |
Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada.
Topics: Adult; Antitubercular Agents; British Columbia; Drug Resistance, Bacterial; Female; Fluoroquinolones | 2017 |
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Thera | 2018 |
Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Female; Humans; Isoniazid; Male; Middle Ag | 2018 |
Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; | 2018 |
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Femal | 2018 |
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Etham | 2018 |
Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
Topics: Adult; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily B; Female; Genotyp | 2019 |
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Duration of Therapy; Etha | 2019 |
Performance of the GenoType MTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse.
Topics: Antibiotics, Antitubercular; Bacterial Proteins; Base Sequence; Brazil; Catalase; DNA-Directed RNA P | 2013 |
Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Proteins; Catalase; Cod | 2013 |
Reactivation of latent tuberculosis in a Crohn's patient after TB prophylaxis treated with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Ant | 2013 |
[Treatment of presumed tuberculous uveitis affecting the posterior segment: diagnostic confirmation and long term outcomes].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Humans; Immunocompromised H | 2013 |
Unfinished battle with childhood tuberculosis: is it curable with less drugs and shorter duration?
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2013 |
Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its association with recurrent tuberculosis in Beijing, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; China; Cohort Studies; Cost of Il | 2014 |
Decision-making dilemma in drug-induced acute pancreatitis.
Topics: Antitubercular Agents; Decision Making; Humans; Isoniazid; Male; Middle Aged; Pancreatitis; Recurren | 2014 |
Correlates of treatment outcomes and drug resistance among pulmonary tuberculosis patients attending tertiary care hospitals of Kolkata, India.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Cross-Sectional Studies; Drug Resistance, Bac | 2014 |
Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up.
Topics: Adult; Antitubercular Agents; Cohort Studies; Female; Follow-Up Studies; Genetic Variation; Genome-W | 2015 |
Treatment outcome of patients with isoniazid mono-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Male; Mid | 2015 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Immigrants and tuberculosis in Hong Kong.
Topics: Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Asia, Southeastern; Asia, Western; | 2015 |
A Girl with Recurrent Pleural Effusion: Immunological Rebound or Isoniazid Induced Lupus?
Topics: Adolescent; Antitubercular Agents; Female; Humans; Isoniazid; Lupus Erythematosus, Systemic; Pleural | 2014 |
Benefit of treatment of latent tuberculosis infection in individual patients.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Femal | 2015 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; F | 2016 |
Repeat exposure to active tuberculosis and risk of re-infection.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Emergency Service, Hospital; E | 2016 |
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Female; Isoniazid; Mice; | 2016 |
Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
Topics: Adult; Antitubercular Agents; Databases, Factual; Drug Administration Schedule; Drug Monitoring; Dru | 2016 |
Drug-resistant tuberculosis among previously treated patients in Yangon, Myanmar.
Topics: Adult; Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; Drug Resis | 2016 |
Tuberculosis presenting as a 'swollen calf'.
Topics: Abscess; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Diagnosis, Different | 2016 |
Takayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection.
Topics: Angiography, Digital Subtraction; Antitubercular Agents; Antiviral Agents; Azathioprine; Female; Flu | 2017 |
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models | 2008 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; | 2008 |
Gynecomastia: a rare adverse effect of isoniazid.
Topics: Adolescent; Antitubercular Agents; Diagnosis, Differential; Gynecomastia; Humans; Isoniazid; Male; P | 2008 |
Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combinatio | 2009 |
[Relapse rate of tuberculosis treated with standard regimen of chemotherapy].
Topics: Adolescent; Aged; Aged, 80 and over; Child; Diabetes Complications; Drug Administration Schedule; Fe | 2009 |
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; HIV Infecti | 2010 |
Risk of relapse and failure after retreatment with the Category II regimen in Nepal.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Cohort Studies; Drug Resistance, Bacterial; F | 2010 |
Predicting outcomes and drug resistance with new standardised treatment.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; Humans; Iso | 2011 |
[Cutaneous reaction after pyrazinamide initiation].
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Eruptions; Drug Therapy, Combination; Dysgeusi | 2011 |
Isoniazid-induced recurrent acute pancreatitis.
Topics: Acute Disease; Antitubercular Agents; Female; Humans; Isoniazid; Pancreatitis; Recurrence; Tuberculo | 2011 |
When tuberculosis comes back: who develops recurrent tuberculosis in california?
Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu | 2011 |
A case of multicentric reticulohistiocytosis responsive to azathioprine in a patient with no underlying malignancy.
Topics: Antitubercular Agents; Azathioprine; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive A | 2011 |
[Sudden decrease in visual acuity and pulmonary infiltrates].
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Laser Coagulation; Ma | 2012 |
Therapeutic drug monitoring in the treatment of tuberculosis patients.
Topics: Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chromatography, High Pr | 2012 |
Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Topics: Adult; Age Factors; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Drug | 2012 |
Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Typing Techniques; Disease Models, Animal; Drug Administra | 2012 |
[Bilateral tuberculous mastitis nulliparous patient, initially treated as idiopathic granulomatous mastitis].
Topics: Adult; Antitubercular Agents; Diagnostic Errors; Drug Therapy, Combination; Ethambutol; Female; Gran | 2012 |
The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD | 2012 |
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Female; HIV Infections; Humans; Isoniazid; Male; Proporti | 2013 |
Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; D | 2012 |
Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Combin | 2002 |
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 2002 |
Seizures in a 13-year-old girl.
Topics: Acidosis; Adolescent; Antitubercular Agents; Asia, Southeastern; Communication Barriers; Diagnosis, | 2003 |
[Mycobacterium tuberculosis resistance to antitubercular agents in Antananarivo in 2000].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Directly Observed Therapy; Drug Resistance, Mult | 2002 |
[The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination; | 2003 |
[Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy].
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male | 2003 |
Preventing recurrent tuberculosis in high HIV-prevalent areas in sub-Saharan Africa: what are the options for tuberculosis control programmes?
Topics: Africa South of the Sahara; Antiretroviral Therapy, Highly Active; Health Policy; HIV Infections; Hu | 2003 |
Reactivation of latent tuberculosis infection in TNF-deficient mice.
Topics: Animals; Cell Migration Inhibition; Chemokines; Down-Regulation; Granuloma; Isoniazid; Lymphocyte Ac | 2003 |
[Relapses after isoniazid treatment].
Topics: Aminosalicylic Acid; Collapse Therapy; Isoniazid; Niacin; Nicotinic Acids; Recurrence; Thiosemicarba | 1954 |
[Indication for and duration of simple oral isoniazid therapy of tuberculous meningitis in children with special reference to the incidence of exacerbations or relapses and the clinical aspects of resistence problems].
Topics: Child; Humans; Incidence; Infant; Isoniazid; Recurrence; Tuberculosis; Tuberculosis, Meningeal | 1958 |
Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate.
Topics: Aged; Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Hospitals; Humans; India; Isoni | 1961 |
Comparative study of isoniazid versus no chemotherapy in the prevention of relapse of chronic cavitary tuberculosis.
Topics: Biomedical Research; Chronic Disease; Isoniazid; Recurrence; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate.
Topics: Aged; Aminosalicylic Acid; Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Follow | 1960 |
[Loss of consciousness with relapse during treatment with Rimifon].
Topics: Child; Chronic Disease; Coma; Consciousness; Humans; Infant; Isoniazid; Recurrence; Tuberculosis; Tu | 1961 |
Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate.
Topics: Aminosalicylic Acid; Chronic Disease; Humans; India; Isoniazid; Recurrence; Tuberculosis; Tuberculos | 1961 |
[Resistance and survival of bacilli in relapses of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Drug Resistance; Drug Resistance, Microbial; Hu | 1963 |
[RELAPSES IN TUBERCULOUS ENCEPHALITIS AND MENINGOENCEPHALITIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Brain Diseases; Child; Encephalitis; Humans; Isoniazid; M | 1962 |
RELAPSE IN TREATED CASES OF PULMONARY TUBERCULOSIS. II. SIX-YEAR FOLLOW-UP OF 109 PATIENTS DISCHARGED FROM THE HOSPITAL WITH MEDICAL APPROVAL, 1955-1956.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Collapse Therapy; Follow-Up Studies; Isoniazid; Pneumonec | 1964 |
[A 27-year-old patient with recurrent Fever].
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Fever; Humans; Isoniazid; Lymph Nodes; Ma | 2003 |
Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.
Topics: Antitubercular Agents; Developing Countries; Drug Resistance, Bacterial; Female; Humans; Isoniazid; | 2004 |
Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Directly Observed Therapy; Drug Combinations; Dr | 2004 |
Long-term outcome of isoniazid prophylaxis against tuberculosis in Chinese renal transplant recipients.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; China; Female; Humans; Isoniazid; Kidney Trans | 2004 |
[Bactericidal therapy in patients with tuberculosis].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Chlortetracycline; Drug R | 2004 |
Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Azathioprine; Endemic Diseases; Female; Glucoc | 2005 |
Reactivation of tuberculosis after apparently adequate chemoprophylaxis.
Topics: Adolescent; Antitubercular Agents; Chemoprevention; Contact Tracing; Disease Transmission, Infectiou | 2005 |
The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation.
Topics: Adult; Antitubercular Agents; Cohort Studies; Directly Observed Therapy; Drug Resistance, Bacterial; | 2006 |
Latent pelvic tuberculosis reactivating in a postmenopausal woman: a case report.
Topics: Aged; Antitubercular Agents; Ethambutol; Female; Hepatitis, Autoimmune; Humans; Hysterectomy; Isonia | 2006 |
[Isoniazid intoxication].
Topics: Acidosis; Anticonvulsants; Antidotes; Antitubercular Agents; Diazepam; Female; Humans; Infusions, In | 2007 |
[Implication of specialized sanatoria in the improvement of care to patients with ocular tuberculosis at the present stage].
Topics: Antioxidants; Antitubercular Agents; Diagnosis, Differential; Glucocorticoids; Hospitals, Special; H | 2007 |
[Mycobacterium ulcerans infection treated by Rifater, pyrazynamide, Myambutol, and surgery: a case report with a 6-year follow-up].
Topics: Anti-Bacterial Agents; Buruli Ulcer; Child; Chloramines; Combined Modality Therapy; Drug Combination | 2008 |
Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chemical and Drug Induced Liver Injury; Drug Administratio | 1984 |
The usefulness of phage typing Mycobacterium tuberculosis isolates.
Topics: Adolescent; Adult; Aged; Animal Diseases; Animals; Bacteriophage Typing; Child; Child, Preschool; Di | 1984 |
[Short-course chemotherapy for tuberculosis in Chile. Operational considerations].
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; P | 1984 |
Prevention of tuberculosis with isoniazid.
Topics: Humans; Isoniazid; Radiography; Recurrence; Time Factors; Tuberculosis | 1983 |
Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid | 1983 |
[Efficacy of pharmaceutical prevention in population groups at high risk for tuberculosis].
Topics: Adolescent; Child; Humans; Isoniazid; Recurrence; Tuberculosis, Pulmonary | 1984 |
[Chemotherapy of tuberculosis--compliance, side effects and incidence of recurrence].
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid | 1983 |
Reactivated musculoskeletal tuberculosis with concomitant asymptomatic genitourinary infection.
Topics: Arthrodesis; Ethambutol; Female; Hip Joint; Humans; Isoniazid; Joint Diseases; Knee Joint; Middle Ag | 1983 |
[Long-term results of an early temporary pneumoperitoneum and chemotherapy in patients with destructive pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Pneumoperitoneum, Artificial; Recurrence; Time Factors; Tube | 1983 |
[Clinical description of the relapse of tuberculosis].
Topics: Drug Resistance, Microbial; Female; Humans; Isoniazid; Male; Middle Aged; Recurrence; Rifampin; Time | 1982 |
[ Effectiveness of treating newly detected tuberculosis without seasonal prophylactic chemotherapy].
Topics: Adolescent; Adult; Aged; Aminosalicylic Acid; Child; Drug Therapy, Combination; Female; Follow-Up St | 1980 |
[Intensive antibacterial therapy of postoperative reactivation of pulmonary tuberculosis].
Topics: Adult; Female; Humans; Isoniazid; Lung; Male; Middle Aged; Postoperative Complications; Powders; Pun | 1981 |
[Problems in treatment of pulmonary tuberculosis: in terms of bacteriologic relapse (author's transl)].
Topics: Drug Therapy, Combination; Humans; Isoniazid; Recurrence; Rifampin; Tuberculosis, Pulmonary | 1980 |
Isoniazid preventive therapy for pulmonary tuberculosis sequelae: which patients up to which age?
Topics: Adult; Age Factors; Aged; Antitubercular Agents; Decision Support Techniques; Humans; Incidence; Iso | 1995 |
Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era.
Topics: Dapsone; Drug Therapy, Combination; Female; Humans; Isoniazid; Leprostatic Agents; Leprosy; Male; Ph | 1994 |
Recurrent acute pancreatitis induced by isoniazid.
Topics: Acute Disease; Adult; Amylases; Humans; Isoniazid; Male; Pancreatitis; Recurrence; Tuberculosis, Pul | 1994 |
Relapse rates in tuberculosis patients.
Topics: Antitubercular Agents; Drug Combinations; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; | 1995 |
Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitu | 1993 |
Silicotuberculosis: long-term outcome after short-course chemotherapy.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Male; | 1995 |
[Ofloxacin-cycloserine-protionamide-INH combination against treatment refractory lung tuberculosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Cycloserine; Dose-Response Relationship, Drug; Drug Ad | 1995 |
4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F | 1994 |
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro | 1994 |
[Acute recurrent toxic encephalopathy++ induced by isoniazide].
Topics: Acute Disease; Adolescent; Brain Diseases; Female; Humans; Isoniazid; Recurrence | 1994 |
Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Isoniazid; London; Lung; Male; Middle Ag | 1994 |
[Clinical aspects and outcome of recurrent pulmonary tuberculosis].
Topics: Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Recurrence; R | 1993 |
[Retreatment of pulmonary tuberculosis--duration of chemotherapy].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Drug Resistance; Female; Follow-Up Studies; | 1993 |
Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status.
Topics: Adolescent; Adult; Aged; Colorado; Emigration and Immigration; Humans; Isoniazid; Mass Screening; Mi | 1993 |
[Indications for chemoprophylaxis of tuberculosis. Arguments for].
Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Child; Child, Preschool | 1993 |
Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes.
Topics: Adult; Aged; Antitubercular Agents; Cause of Death; Clinical Protocols; Cohort Studies; Female; Fore | 1997 |
[The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako].
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Comb | 1997 |
Drug-resistant tuberculosis in Singapore, 1995 to 1996.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Anti | 1997 |
[HPLC study of blood isoniazid in patients with tuberculosis in Tunisia: significance and therapeutic results].
Topics: Acetylation; Aged; Antitubercular Agents; Chromatography, High Pressure Liquid; Humans; Isoniazid; M | 1995 |
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi | 1998 |
Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
Topics: Adult; Ambulatory Care; Antibiotics, Antitubercular; Antitubercular Agents; Cohort Studies; Confiden | 1998 |
[Recurrent tuberculosis in a psychiatric hospital, recurrent outbreaks during 1987-1996].
Topics: Antitubercular Agents; Disease Outbreaks; Drug Therapy, Combination; Follow-Up Studies; Hospitals, P | 1998 |
[Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide].
Topics: Aged; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethambutol; Exanthema; Female | 1998 |
-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethamb | 1998 |
[Efficacy of unfixed continuation phase short-course chemotherapy].
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follo | 1997 |
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 1999 |
[Fenazide efficiency in combined chemotherapy of new and relapsing pulmonary tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Evaluation; Ferrous Compound | 2000 |
Trends in antituberculosis drug resistance in Karonga District, Malawi, 1986-1998.
Topics: Adult; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; HIV Seropositivity; Hu | 2000 |
Primary and acquired resistance of Mycobacterium tuberculosis in Western Mexico.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Isoniazid; Mex | 2000 |
Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Drug Therapy | 2000 |
[The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabe | 2000 |
Effect of preoperative chemotherapy on the outcome of surgical treatment of vertebral tuberculosis: retrospective analysis of 434 cases.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Combined Modality Therapy; Debridement; Drug | 2001 |
Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis.
Topics: Adolescent; Adult; Antitubercular Agents; Culture Media; Fatal Outcome; Female; Humans; Isoniazid; M | 2001 |
A 23-year-old with refractory seizures following an isoniazid overdose.
Topics: Adult; Anticonvulsants; Drug Overdose; Follow-Up Studies; Humans; Isoniazid; Male; Recurrence; Risk | 2002 |
Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Typing Techniques; DNA Fi | 2002 |
Results of treatment of spinal tuberculosis by "middle-path" regime.
Topics: Abscess; Aminosalicylic Acids; Antitubercular Agents; Convalescence; Debridement; Drug Therapy, Comb | 1975 |
Short-course chemotherapy for pulmonary tuberculosis.
Topics: Africa, Eastern; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Drug Thera | 1975 |
Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis.
Topics: Drug Therapy, Combination; Humans; Isoniazid; Patient Dropouts; Recurrence; Rifampin; Streptomycin; | 1977 |
Tuberculosis after corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Airway Obstruction; Arthritis, Rheumatoid; Dermatitis, Exfolia | 1976 |
Relapsing meningoencephalitis ? cerebral sarcoidosis.
Topics: Adrenocorticotropic Hormone; Adult; Aminosalicylic Acids; Brain Diseases; Dexamethasone; Diagnosis, | 1975 |
[Current short-term chemotherapy of tuberculosis. Fundamentals, assumptions, drug combinations, plan of treatment and prospects].
Topics: Aminosalicylic Acid; Antitubercular Agents; Drug Evaluation; Drug Therapy, Combination; Ethambutol; | 1978 |
[Experience with the use of the express intravenous administration of isoniazid to tuberculosis patients].
Topics: Adult; Aged; Chronic Disease; Female; Humans; Injections, Intravenous; Isoniazid; Male; Middle Aged; | 1979 |
Silicosis and tuberculosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Ethionamide; Humans; Isoniazid; Male; | 1979 |
Long-term results of medical treatment in Mycobacterium intracellulare infection.
Topics: Adult; Aged; Drug Therapy, Combination; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Male; Mi | 1979 |
[New guidelines for pulmonary tuberculosis therapy].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Recurrence; Rifamp | 1978 |
Retreatment of drug-sensitive relapses of pulmonary tuberculosis following chemotherapy with standard drugs.
Topics: Aminosalicylic Acid; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rec | 1976 |
Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months.
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Microbial; Hong K | 1977 |
Reactivation of tuberculosis in old age.
Topics: Adult; Aged; Child; Ethambutol; Female; Humans; Isoniazid; Male; Recurrence; Rifampin; Tuberculosis, | 1977 |
Practical management and control of tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Chemical and Drug Induced Liver Injury; Child; Drug Therapy, Combinati | 1977 |
An assessment of the need for follow-up of patients with pulmonary tuberculosis adequately treated by chemotherapy.
Topics: Aminosalicylic Acids; Attitude to Health; Follow-Up Studies; Isoniazid; Physician-Patient Relations; | 1975 |
Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii.
Topics: Adult; Drug Resistance, Microbial; Ethambutol; Female; Humans; Isoniazid; Lung Diseases; Male; Mycob | 1975 |
Proceedings: Latest results of East African/British Medical Research Council short course chemotherapy studies.
Topics: Drug Evaluation; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Streptomycin; Tuberculosis | 1975 |
Destructive forms of renal tuberculosis.
Topics: Humans; Isoniazid; Kidney Function Tests; Nephrectomy; Prognosis; Radiography; Recurrence; Renal Art | 1975 |
Reactivation of tuberculous lymphadenitis during pregnancy.
Topics: Adult; Female; Humans; Isoniazid; Mycobacterium tuberculosis; Pregnancy; Pregnancy Complications, In | 1992 |
Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin.
Topics: Arkansas; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans | 1992 |
Contemporary management of cervical tuberculosis.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Biopsy, Needle; Ethambutol; Female; Humans; Isoniazid; Male; | 1992 |
Papulonecrotic tuberculid. Necessity of long-term triple regimens.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Combinations; Ethambutol; Female; Humans; Isoniazid; | 1991 |
[Dynamics of specific changes in recurrences of pulmonary tuberculosis in relation to chemotherapy schedules].
Topics: Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Humans; Is | 1991 |
A new short-term combination therapy of leprosy.
Topics: Adult; Aged; Drug Therapy, Combination; Erythema Nodosum; Female; Follow-Up Studies; Humans; Isoniaz | 1991 |
[Standardized controlled antitubercular therapy and results in 755 patients].
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid | 1991 |
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antitubercular Agents; Humans; Isoniazid; Male; Recurrenc | 1991 |
A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Aspartate Aminotransferases; Cost-Benefit Analysis; | 1990 |
The mycobacteriology of pulmonary tuberculosis in South African gold miners.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Isoniazid; Male; Mining; Mycobacterium tu | 1990 |
[The effect of anti-recurrence treatment with isoniazid in combination with etimizol on the immune reactivity of Group III ambulatory care patients].
Topics: Adult; Aged; Ambulatory Care; Drug Therapy, Combination; Etimizol; Female; Humans; Immunity; Isoniaz | 1990 |
[Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load].
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male | 1990 |
[Approach to chemotherapy of vertebral tuberculosis].
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Recurren | 1990 |
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice.
Topics: Animals; Anti-Bacterial Agents; Disease Susceptibility; Drug Therapy, Combination; Female; Immunity, | 1989 |
[Immediate and long-term results of the combined treatment of patients with extensive destructive tuberculosis of the lungs].
Topics: Adult; Ethionamide; Female; Follow-Up Studies; Glucocorticoids; Humans; Isoniazid; Male; Middle Aged | 1989 |
Exogenous reinfection with tuberculosis in a shelter for the homeless.
Topics: Adult; Alcoholism; Boston; Drug Resistance, Microbial; Housing; Humans; Ill-Housed Persons; Isoniazi | 1986 |
[Long-term results of short-course chemotherapy in pulmonary tuberculosis (final report). The third study: comparative study of two regimens, 6RHZ and -6RHS (treatment was continued for 6 months after negative conversion of sputum by culture)].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male; Middle A | 1988 |
Rifampicin-isoniazid and delayed elimination of theophylline: a case report.
Topics: Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Lung D | 1988 |
First assessment of the Malta Leprosy Eradication Project.
Topics: Dapsone; Drug Combinations; Drug Therapy, Combination; Evaluation Studies as Topic; Follow-Up Studie | 1986 |
[Investigation on bacteriological relapses in cases of pulmonary tuberculosis treated with INH and RFP--report of the 27th B series of controlled trials of chemotherapy. Cooperative Study Unit of Chemotherapy of Tuberculosis of National Sanatoria in Japan
Topics: Adult; Aged; Female; Humans; Isoniazid; Male; Middle Aged; Recurrence; Rifampin; Time Factors; Tuber | 1987 |
[Role of chemical prevention of tuberculosis in current epidemiologic situations].
Topics: Adult; Carrier State; Humans; Isoniazid; Recurrence; Time Factors; Tuberculosis, Pulmonary | 1987 |
[Studies of short-term chemotherapy of tuberculosis. III. Early and late results of 6 months' treatment of tuberculosis. Analysis of failures and recurrences during 1-5 years' observation].
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Ma | 1986 |
[Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
Topics: Adult; Algeria; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Eth | 1986 |
[Antitubercular therapeutic regimens routinely prescribed in Bas-Rhin and results of treatment].
Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Antitubercular Agents; Drug Administration Schedule | 1986 |
Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees.
Topics: Adolescent; Adult; Asia, Southeastern; Asian; Child; Drug Resistance, Microbial; Female; Humans; Iso | 1986 |
Sarcoidosis, pulmonary hypertension, and acquired peripheral pulmonary artery stenosis.
Topics: Adult; Cardiac Catheterization; Constriction, Pathologic; Female; Heart Murmurs; Humans; Hypertensio | 1985 |
[Chemoprophylaxis of persons in dispensary registration group VII taking into account the risk factors of tuberculosis reactivation].
Topics: Adult; Antitubercular Agents; Drug Evaluation; Female; Humans; Isoniazid; Male; Middle Aged; Recurre | 1985 |
Supervised ambulatory treatment of tuberculosis with brief initial hospitalization.
Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Aminosalicylic Acids; Capreomycin; Convalescence; D | 1973 |
Short-course treatment in pulmonary tuberculosis.
Topics: Adolescent; Adult; Africa, Eastern; Antitubercular Agents; Humans; Isoniazid; Mycobacterium tubercul | 1973 |
Follow-up of patients with pulmonary tuberculosis adequately treated by chemotherapy: is this really necessary?
Topics: Adult; Age Factors; Aminosalicylic Acids; Carcinoma, Bronchogenic; Female; Follow-Up Studies; Humans | 1974 |
Letter: Rifampicin and cortisone replacement therapy.
Topics: Addison Disease; Aged; Cortisone; Drug Interactions; Female; Humans; Isoniazid; Recurrence; Rifampin | 1974 |
Productivity of prolonged follow-up after chemotherapy for tuberculosis.
Topics: Aminosalicylic Acids; Female; Follow-Up Studies; Humans; Isoniazid; Male; Mycobacterium tuberculosis | 1973 |
Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing.
Topics: Aminosalicylic Acids; Bacteriophage Typing; Drug Resistance, Microbial; Ethambutol; Ethionamide; Hum | 1973 |
Progress of tuberculous diabetes coming under supervision during the years 1953-65 up to July 1972.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Child; Coronary Disease; Diabetes Complications; Drug | 1973 |
[Pulmonary tuberculosis resistant to streptomycin and isoniazid and treated wtih a combination of ethionamide, pyrazinamide, and cycloserine (200 cases)].
Topics: Adolescent; Adult; Age Factors; Aged; Aminosalicylic Acids; Child; Cycloserine; Drug Resistance, Mic | 1973 |
Rifampin plus isoniazid in initial therapy of pulmonary tuberculosis and rifampin and ethambutol in retreatment cases.
Topics: Bilirubin; Drug Eruptions; Drug Hypersensitivity; Ethambutol; Humans; Isoniazid; Mycobacterium tuber | 1972 |
Treatment of drug-resistant tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Dr | 1971 |
On the epidemiology of tuberculosis in some selected countries. Highlights and prospects for control and eradication. II.
Topics: Adolescent; Aftercare; Antitubercular Agents; BCG Vaccine; Child; Comprehensive Health Care; Coopera | 1971 |
[Duration of the after-control of the tuberculous patients following the termination of the treatment].
Topics: Adolescent; Adult; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide | 1972 |
[Comparative study on an intermittent mode of pulmonary tuberculosis therapy using streptomycin and isoniazid].
Topics: Adolescent; Adult; Ambulatory Care; Aminosalicylic Acids; Drug Therapy, Combination; Humans; Isoniaz | 1974 |
Twenty years of bone and joint tuberculosis in Bradford. A comparison of the disease in the indigenous and Asian populations.
Topics: Adolescent; Adult; Age Factors; Aged; Aminosalicylic Acids; Asia; Blood Sedimentation; Child; Child, | 1974 |
Side effects of rifampicin. A clinical study.
Topics: Acute Disease; Acute Kidney Injury; Adult; Ambulatory Care; Amylases; Chemical and Drug Induced Live | 1973 |
Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Child; Child, Preschool; Drug E | 1974 |
A study of 200 cases of active, recent pulmonary tuberculosis treated with rifampin-isoniazid. A follow-up history of one and one-half to three years.
Topics: Adolescent; Adult; Aged; Bilirubin; Drug Resistance, Microbial; Ethambutol; Female; Follow-Up Studie | 1972 |
Relapsing tuberculous meningitis complicated by late sequelae.
Topics: Adult; Aminosalicylic Acids; Arachnoiditis; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Gluco | 1972 |
The effect of acceptable and adequate outpatient treatment on the length of hospitalization and on readmission for relapse or reactivation of pulmonary tuberculosis.
Topics: Adolescent; Adult; Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Child, Preschool; D | 1973 |
[Hospital chemotherapy in the presence of isoniazid-resistant and multi-resistant causative organisms].
Topics: Aged; Antitubercular Agents; Chronic Disease; Drug Combinations; Drug Resistance, Microbial; Humans; | 1973 |
Pulmonary tuberculosis in well-treated alcoholics. Long-term prognosis regarding relapses compared with non-alcoholic patients.
Topics: Alcoholism; Aminosalicylic Acids; Follow-Up Studies; Humans; Isoniazid; Prognosis; Recurrence; Strep | 1972 |
[Problems in the administration of preventive treatment of tuberculosis].
Topics: Aminosalicylic Acids; Communicable Disease Control; Humans; Isoniazid; Recurrence; Streptomycin; Tub | 1972 |
Shorter treatment.
Topics: Animals; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Time Factors; Tub | 1972 |
Relapse in tuberculosis. A report from the Research Committee of the South-East Metropolitan Regional Thoracic Society.
Topics: Adolescent; Adult; Age Factors; Aged; Aminosalicylic Acids; Drug Resistance, Microbial; Female; Huma | 1973 |
Development of pulmonary tuberculosis several years after chemoprophylaxis.
Topics: Adult; Female; Health Education; Humans; Isoniazid; Male; Recurrence; Tuberculosis, Pulmonary | 1973 |
A second reversion of the tuberculin reaction after issoniazid prevention therapy. A case report.
Topics: Adult; Female; Humans; Isoniazid; Recurrence; Tuberculin Test; Tuberculosis, Pulmonary | 1973 |
[Experience with prolonged treatment against relapses in pulmonary tuberculosis].
Topics: Adult; Aminosalicylic Acids; Female; Humans; Isoniazid; Male; Middle Aged; Recurrence; Time Factors; | 1973 |
Successive manifestations of tuberculosis in a recalcitrant patient.
Topics: Adult; Aminosalicylic Acids; Communicable Disease Control; Hospitalization; Humans; Isoniazid; Male; | 1973 |
[Modern treatment of tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Recur | 1973 |
High dose ethambutol; an oral alternate for intermittent chemotherapy.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etha | 1974 |
Letter: Massive use of chemoprophylaxis against tuberculosis.
Topics: Adult; BCG Vaccine; Child; Humans; Infant, Newborn; Isoniazid; Recurrence; South Africa; Tuberculosi | 1974 |
Factors affecting the outcome of treatment of pulmonary tuberculosis in sub-optimal conditions: an 18-month follow-up of 224 patients.
Topics: Absenteeism; Adult; Age Factors; Aged; Attitude to Health; Developing Countries; Drug Resistance, Mi | 1971 |
A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Cycloserine; Ethionamide; Gastrointestina | 1969 |
Reactivation of inactive tuberculosis in Northern Canada.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Canada; Child; Female; Hospitalization; Humans; Inuit | 1971 |
[Rheumatoid pleurisy (apropos of an observation].
Topics: Arthritis, Rheumatoid; Biopsy; Diagnosis, Differential; Humans; Isoniazid; Male; Middle Aged; Pleuri | 1970 |